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ABSTRACT 
 
Mark Schliekelman: Characterization of a murine hypomorphic allele of the spindle 
checkpoint gene Bub1 and its role in tumorigenesis 
(Under the direction of Terry Van Dyke) 
 
Bub1 is a serine/threonine kinase originally described as a core component of the spindle 
assembly checkpoint (SAC) mechanism in yeast. We produced mice harboring a Bub1 
mutant allele lacking exons 2 and 3, resulting in a hypomorphic mutant expressed at less than 
5% of wt levels. Despite this significant reduction, homozygous mutant animals are viable on 
a mixed 129P2/B6 or FVB background but display increased tumorigenesis with aging, 
whereas mice with a C57Bl/6J background die perinatally. Bub1 mutant murine embryonic 
fibroblasts (MEFs) display defects in chromosome congression to the metaphase plate, severe 
chromosome missegregation and aneuploidy accompanied by high levels of premature 
senescence. Mutant MEFs have a robust SAC in response to nocodazole treatment, but an 
impaired response to Taxol. The significant reduction in SAC response to Taxol but not 
nocodazole, coupled with the reduced binding of BubR1 but not Mad2, indicates that Bub1 is 
particularly critical for the SAC response to a lack of tension on kinetochores.  In light of the 
tumor suppressor p53’s role in induction of senescence and prevention of aneuploidy, we 
assessed inactivation of p53 in Bub1 mutant MEFs.  p53 loss eliminates increased senescence 
in Bub1∆2-3/∆2-3 MEFs, but does restore proliferation in Bub1∆2-3/∆2-3 MEF cultures or rescue 
perinatal lethality of Bub1∆2-3/∆2-3 animals.  Despite its role as a guardian of genomic integrity, 
p53 inactivation does not increase aneuploidy in Bub1 mutant cells.  
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CHAPTER 1 
INTRODUCTION 
 
Human cancer encompasses a wide variety of diseases that occur in many tissues and 
cell types with different attributes.  A key feature of cancer is the high level of genetic 
diversity in tumors.  It is generally accepted that multiple genetic changes are necessary for 
initiation of tumor development, particularly in oncogenes, to stimulate proliferation, and 
tumor suppressors, to allow that proliferation to continue unchecked.  For example, 
colorectal cancers accumulate a specific sequence of mutations, typically inactivation of APC, 
followed by mutation of KRAS, p53 and others (1).  With most tumors developing many 
genetic alterations, it has been theorized the normal mutation rate in human cells is likely not 
sufficient and requires an increased level of genetic instability (2).  Genetic instability can 
occur at the gene level with nucleotide alterations primarily due to faulty DNA repair 
mechanisms, at the genome level with microsattelite instability and chromosomal changes, or 
with epigenetic changes (3;4).  Genomic instability in the form of aneuploidy or the gain and 
loss of whole chromosomes is found in the majority of human tumors.  As of yet there is no 
conclusive evidence that aneuploidy is a contributing factor to tumorigenesis versus merely 
being a byproduct of misregulated cellular control, but several pieces of evidence suggest 
aneuploidy does aid tumorigenesis.  First, aneuploidy has been identified in many 
precancerous tissues including colon, brain, lung, breast and others (5).  In addition, 
aneuploidy has been detected in the tissues of carcinogen-treated animals prior to tumor 
development (6-9). Second, aneuploidy precedes transformation after infection with the 
SV40 tumor virus and other DNA viruses specifically target cellular mechanisms for 
preventing aneuploidy(10).  Third, non-random aneuploidies have been identified that 
associate with specific events of tumorigenesis such as invasiveness, metastasis and drug 
resistance(11-13).  Finally, aneuploidy rates correlate with tumor progression and aneuploid 
tumors show a poor response to therapy (14;15).  Generating resistance to chemotherapy 
likely requires a very high rate of genetic change, and aneuploidy is the quickest way of 
significantly modifying the genome.  
 Loss or gain of chromosomes can occur in several ways: chromosomal 
missegregation after undergoing polyploidy, centrosome duplication, failure of sister 
chromatid cohesion, and errors of the spindle assembly checkpoint.  Polyploidy due to either 
cell fusion, endoreduplication or cytokinesis failure results in a duplication of the normal 
chromosomal complement (16).  If a polyploid cell continues cycling and attempts to 
segregate its chromosomes, the increased ploidy increases the likelihood of aneuploidy 
(17;18).  Duplication of centrosomes, the microtubule organizing center during mitosis, 
frequently leads to aneuploidy, as chromosomes may fail to biorient in a cell with more than 
two centrosomes (19; 20).  Centrosomes are replicated during S phase and incorrect 
centrosome numbers can result from endoreduplication events in which the genome and 
centrosomes are replicated but do not progress through mitosis or with loss of regulatory 
proteins such as p53 that are required for controlling centrosome duplication (21).  Finally, 
aneuploidy can result from failure of the spindle assembly checkpoint, the major mechanism 
for delaying anaphase until all chromosomes are attached to spindle fibers and bioriented 
(see reviews (22;23)).  
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 Mitosis is a complicated process that must be tightly regulated to ensure each 
daughter cell receives the correct complement of chromosomes.  Following replication of the 
DNA during S phase, a cell will pause briefly at the G2 checkpoint before proceeding into 
mitosis.  The first phase of mitosis, prophase, is characterized by condensation of the 
chromatin, centrosome separation and spindle formation, and finally nuclear breakdown.  
Nuclear envelope breakdown marks the end of prophase and the beginning of prometaphase, 
the next stage of mitosis.  During prometaphase, centrosomes align at opposite ends of the 
cell and microtubules emanating from the centrosomes or spindle poles bind to individual 
chromatids at the kinetochore, a multi-protein structure at the centromere.  Spindle fibers 
from the opposite spindle poles search out kinetechores by lengthening and contracting, 
pulling the chromosomes to the center of the cell to achieve biorientation (see Figure 1).  
Once all chromosomes have lined up at the center of the cell, the proteins holding the sister 
chromatids together are cleaved and the sister chromatids are pulled to opposite sides of the 
cell, a stage known as anaphase.  When the separate bodies of chromatids reach the opposite 
ends of the cell, telophase, the final mitotic stage begins.  During telophase, the chromatids 
decondense, spindle fibers breakdown, and nuclear envelope reform before undergoing 
cytokinesis and completing the separation into two daughter cells.   
 
The Spindle Assembly Checkpoint 
The major mechanism for preventing premature entry into anaphase is the spindle assembly 
checkpoint (SAC). While the classical definition of a checkpoint implies it is not activated 
during every cell cycle, the SAC works both as a checkpoint and timing mechanism for 
ensuring mitotic fidelity.  The SAC’s primary role is to delay sister chromatid separation and 
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anaphase onset until all chromosomes achieve bipolar attachment to microtubules at the 
metaphase plate.  Sister chromatids are held together by proteins called cohesins and 
separation of the chromosomes requires the destruction of cohesion by the protease separase 
(24).  Prior to anaphase, separase is maintained in an inactive form through inhibition of 
securin.  In order for sister chromatids to separate and mitosis to progress into anaphase, the 
E3 ubiquitin ligase APC/C (the anaphase promoting complex or cyclosome) and specificity 
factor cdc20 target securin for degradation, allowing the breakdown of cohesion.   The SAC 
maintains chromosome stability through regulation of the APC/cdc20 complex, by direct 
binding of cdc20 to inhibit its interaction with APC/C as well as through the activity of 
mitotic kinases that phosphorylate cdc20 (Figure 2) (25).  The core components of the 
Spindle Assembly Checkpoint- Bub1, Bub3, Mad1, Mad2, Mad3 and MPS1- were originally 
identified in genetic screens with yeast mutants that failed to arrest in mitosis after exposure 
to spindle poisons (26;27).  The inhibition of Cdc20 is primarily performed through binding 
by Mad2 and BubR1, which form the mitotic checkpoint complex (MCC), along with Bub3 
(28-31).  Kinetochore localization and activation of the MCC require Bub1 and Mad1 which 
appear to function as a scaffold for other proteins at the kinetochore (32;33).  
The triggering stimulus that activates the spindle checkpoint remains controversial.  
Current evidence suggests that the spindle checkpoint detects lack of kinetochore-
microtubule attachment, lack of tension on microtubules at the kinetochore, or both (34).  
The fact that kinetochore tension facilitates microtubule attachment and unattached 
microtubules are not under tension has made it difficult to distinguish these possibilities(35). 
Nevertheless, it is clear that the presence of even one unattached kinetechore is sufficient to 
activate the SAC and inhibit progression into anaphase (36).  The mechanism of APC/Cdc20 
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inhibition by SAC is multi-tiered, including inhibitory binding of Mad2 and BubR1(Mad3L) 
to cdc20 and Bub1-mediated inhibitory phosphorylation of APC/Cdc20 (24). Distinct 
inhibitory pathways may be activated by different conditions (e.g. loss of microtubule 
attachment vs. loss of tension), although it remains unclear whether the different regulatory 
mechanisms function in separate pathways or as part of an integrated signaling system.  
Mad2 localizes to unattached kinetochores, but not to attached kinetochores lacking tension 
whereas BubR1 and Bub1 localize to kinetochores after both loss of attachment and tension 
(37;38).   It is clear Mad2 and BubR1 work synergistically to inhibit cdc20, but BubR1 is a 
much more powerful inhibitor of the APC/cdc20 complex and may be capable of responding 
to loss of tension without Mad2 (30;31;39). 
Studies in model organisms support a crucial role for the SAC, even though the 
magnitude of SAC requirement differs among organisms. Yeasts lacking core SAC 
components grow normally under unperturbed conditions, yet display increased rates of 
chromosome missegregation and are unable to grow in the presence of spindle poisons such 
as nocodazole (40-42).  Deletion or suppression of SAC gene homologs in Drosophila and C. 
elegans generally causes severe mitotic defects and chromosome missegregation (43-46), 
although Mad2 appears to be dispensable in flies (46). To date, all characterized null 
mutations of core spindle checkpoint components in mice, including Mad1, Mad2, Bub3, and 
BubR1 (Mad3L), cause early embryonic lethality (47-50). Heterozygous animals were viable 
in each case, but displayed evidence for haploinsufficiency of SAC function.  Mouse 
embryonic fibroblasts (MEFs) heterozygous for Bub3 failed to arrest in response to spindle 
ablation, while Mad2 and BubR1 heterozygous MEFs have high levels of mitotic 
abnormalities (51-53).  While complete disruption of the SAC causes early embryonic 
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lethality and haploinsufficiency is compatible with viability, strong reduction of BubR1 via a 
hypomorphic allele causes intermediate phenotypes. The BubR1hy/null animals die perinatally, 
while BubR1hy/hy animals survive, but display growth retardation and progeroid features (53).  
Both genotypes are associated with severe aneuploidy in MEFs, and a lack of checkpoint 
response to nocodazole.  The data from BubR1 mutant mice also suggest that severe 
chromosome instability may cause cellular senescence. Recent studies indicate that 
senescence acts as a tumor suppression mechanism in vivo, consistent with the relatively 
modest increase in tumor formation observed in BubR1 mutant mice (54;55).  The results 
from these models indicate that some minimal SAC activity is essential for early embryonic 
development but significantly reduced SAC function can be tolerated in mice at the expense 
of genomic stability.  
 While chromosome instability (CIN) had frequently been observed in tumors, the 
discovery of Bub1 mutations in colorectal cancer cell lines by Cahill et al.(1998) led to 
increased interest in the role of mitotic regulation in tumorigenesis (56).  In the years 
following this initial discovery, a large number of studies examined mutation of SAC genes 
in various cancers and cancer cell lines.  Examination of tumors and cancer lines for mitotic 
regulatory function in lung cancer cell lines (57), hepatocellular carcinomas(58), aneuploid 
breast cancer lines(59), HNSCC cell lines(60) and hepatoma cell lines(61) all found high 
incidences of mitotic arrest impairment, but only the hepatoma cell lines had an observable 
disruption of sequence or expression in a SAC gene.  Specific mutations of SAC genes are 
rare in cancers although Bub1 and BubR1 mutations have been noted in ATLL samples and 
colorectal cancer cell lines (62) and Mad2 mutation in gastric cancers (63).  Changes in gene 
expression appear to be much more prevalent, with increases and decereases in expression of 
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SAC genes being found in tumor samples, although some of these changes in expression 
could be a response to other events in tumorigenesis.  In addition to incidents of SAC 
disruption in sporadic cancers, mosaic variegated aneuploidy (MVA), a rare inherited 
syndrome characterized by early tumor development and developmental defects results from 
biallelic mutation of BubR1 (64).  Studies in mice also demonstrate a role for SAC genes in 
preventing tumorigenesis.  While complete loss of core SAC genes is embryonic lethal, mice 
heterozygous for Mad2, Bub3, BubR1 and Mad1 all show increased tumor incidence with 
aging or carcinogen treatment (50-52;65).  Mice overexpressing Mad2 also show an 
increased tumor incidence with increased mitotic aberrancies, highlighting that both reduced 
and increased expression of SAC genes can contribute to tumorigenesis (66).  Interestingly, 
they found that continuous overexpression of Mad2 was not required for tumor formation, 
adding additional evidence for chromosomal instability as an initiating event in 
tumorigenesis. 
Complicating the role of the SAC in tumor development are observations indicating 
that some SAC components have roles in chromosome segregation or other functions in 
addition to their roles in the SAC.  The magnitude of chromosome missegregation in yeast 
SAC gene mutants under normal growth conditions varies widely, with relatively modest 
increases in mad1, 2 and 3 mutants, and much higher instability in Bub1 and Bub3 mutants, 
indicating differences in the roles of these genes outside of arresting mitotic progression.  
The MPS1 kinase is required for the SAC, but also for centrosome duplication (67) and Bub1 
has roles in chromosome congression (68) and maintenance of sister chromosome cohesion 
(69).  Both BubR1 and Mad2 appear to regulate mitotic timing – a role that may be partially 
separate from their SAC roles and BubR1 is also involved in DNA damage response (70;71). 
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Thus the phenotypes associated with SAC gene deletion may be more severe than that 
predicted by loss of the core SAC activity, and the role of the SAC in development of 
aneuploidy and tumorigenesis is unclear. 
 
Bub1 
 The spindle assembly checkpoint protein Bub1 is a serine/threonine kinase that localizes at 
kinetochores during mitosis and mediates efficient kinetochore localization of other SAC 
components.  In addition to the C-terminal kinase domain, Bub1 contains kinetochore 
localization domain and a highly conserved N-terminal domain (72-74).  First identified in 
screens of yeast mutants for mitotic regulatory components, Bub1 deletion causes high 
chromosome missegregation rates under normal growth conditions and lethality under 
perturbed conditions (41).  In yeasts, Bub1’s roles in SAC activity and chromosome 
segregation are separable, with the N-terminal domain being required for kinetochore 
localization and checkpoint functions, while the C-terminal kinase domain is required to 
prevent chromosome lagging and missegregation during mitosis (40).  Studies in vertebrate 
systems have been confined to biochemical or cell culture models, and have produced 
sometimes conflicting results about Bub1’s roles in mitotic regulation.   
Bub1 was originally identified as part of the spindle assembly checkpoint, but its 
necessity for proper spindle checkpoint function in higher organisms has been controversial.  
Taylor and Mckeon (1997) first demonstrated the requirement of mammalian Bub1 for SAC 
activity with expression of a dominant-negative Bub1 protein that proved to inhibit mitotic 
arrest in the presence of nocodazole (72).  Subsequent work in xenopus extracts supported 
the essential nature of Bub1 for spindle checkpoint arrest and these experiments further 
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demonstrated that the bulk of this activity is performed by the N-terminus, with minor 
requirements for the kinase functions (74;75).  Successive work in mammalian cell culture 
systems have provided mixed data, with some studies demonstrating an essential role for 
Bub1 (76;77) while others did not find Bub1 to be necessary for spindle checkpoint function 
(68).  These discrepancies may be partly explained by differential levels of knockdown, the 
cell type in which the studies were conducted, and the way in which spindle checkpoint 
function is assessed.  Most likely Bub1 is not required for all spindle checkpoint activation, 
but is necessary for a functional spindle checkpoint.  
Bub1 localizes to kinetochores early in mitosis in an Aurora B-dependent manner and 
remains attached until anaphase (38).  In Xenopus extracts, Bub1 localization to kinetochores 
is followed by several other core SAC proteins, as antibody depletion of Bub1 reduces 
staining at kinetochores of Mad1,Mad2, and CENP-E (75).  Further work by Johnson et al. 
(2004) in mammalian cells delineated an order for the localization of spindle checkpoint 
proteins at the kinetochores with Bub1 localizing first, followed by Cenp-F, Bubr1, Cenp-E 
and Mad2 (68).  However, it is evident that efficient localization of Mad2 and BubR1 is not 
required for all activations of the spindle checkpoint, as cells will still arrest in nocodazole 
after sufficient Bub1 depletion to inhibit kinetochore localization of these proteins.  Recent 
work has also demonstrated a role for localization of inner kinetochore proteins as well, 
which are primarily involved in sister chromatid cohesion and microtubule attachment (78).  
The protein shugoshin, a protector of cohesion, is dependent on Bub1 for centromeric 
localization (69;77).  Depletion of Bub1 or Shugoshin in HeLa cells both cause 
missegregation of chromosomes and loss of cohesion in these cells activates mitotic arrest 
via Mad2 and AuroraB. 
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While the kinase domain of Bub1 appears to be dispensable for spindle checkpoint 
function in yeast, Bub1 kinase activity is likely important for modulating APC/cdc20 activity 
in higher organisms.  Bub1 phosphorylates itself, in the conserved N-terminal domain, as 
well as Mad1 and cdc20 (79;80).  Cdc20 has Bub1 dependent phosphorylation sites, and 
expression of a cdc20 mutant in Hela cells that lacks these phosphorylation sites partially 
compromises the spindle checkpoint.  In Xenopus extracts depleted of Bub1, a kinase dead 
Bub1 is able to restore SAC activity in response to high levels of nocodazole, but not low 
doses of nocodazole (74).  Thus it is likely that Bub1 is necessary for responding to low 
levels of SAC stimulation, although assessing the role of Bub1 for SAC function is 
complicated by the activating stress as evidence suggests a more important role for Bub1 in 
responding to loss of tension than loss of attachment.  Skoufias et al. (2001) found that while 
mammalian Bub1 and BubR1 localize to kinetechores in the presence of low concentrations 
of vinblastin, Mad2 does not, suggesting separate pathways for response to conditions that 
alter tension on microtubules versus complete ablation (39).  Similarly in Xenopus extracts, 
Bub1 mutants were unable to phosphorylate histone H1, an indicator of SAC activity, at low 
doses of nocodazole, but had normal kinase function at high nocodazole doses.  Likewise, 
depletion of Bub1 in mouse oocytes resulted in premature entry into anaphase treatment of 
low doses of nocodazole (81).  Together these data suggest Bub1 is more important to 
responding to a loss of microtubule tension, or at least to a lower activating level of the 
spindle checkpoint. 
While data are still mixed regarding Bub1’s exact role in the spindle checkpoint, 
mounting evidence suggests it is indeed a tumor suppressor.  As mentioned previously, Bub1 
mutations have been found in several types of tumors and Bub1 expression is lower in some 
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colorectal cancers, but overexpressed in most (82).  Bub1 mutations were frequently found in 
thymic lymphomas from Brca2 mutant mice (83).  In addition, oncogenic SV40 large T 
antigen binds Bub1 and disrupts spindle checkpoint function (84).  In mice, Bub1 is 
upregulated during SV40 Tag induced prostate cancer, and these tumors develop aneuploidy, 
but some Bub1 function is required for growth in human prostate cancer cell lines as 
knockdown of Bub1 results in reduced cell proliferation (85).  Thus while disrupted Bub1 
can lead to aneuploidy and potentially contribute to tumorigenesis, too much reduction in 
Bub1 function perturbs cell proliferation.  There is also evidence for Bub1 being involved in 
apoptosis and senescence induction.  HeLa cells with partially reduced Bub1 undergo a 
caspase-indendent cell death after exposure to mitotic poisons, whereas aneuploidy 
developed when Bub1 was completely depleted (86).  Expression of a dominant negative 
Bub1 in murine cells also reduced apoptosis in response to spindle poison although 
overexpressing the same dominant negative Bub1 in murine thymocytes did not increase 
thymic tumor predisposition (72;87).  Inactivating Bub1 in human fibroblasts delayed 
senescence after growth in soft agar and transplantation into nude mice (88) and Bub1 was 
identified in a screen for genes that bypass senescence with loss of function (89).  In contrast, 
loss of Bub1 has also been observed to activate p53 dependent senescence pathways in 
primary human fibroblasts(90).  In summary, while Bub1 does act as a tumor suppressor, the 
exact manner in which it prevents tumorigenesis is still debated. 
 
P53 and chromosome instability 
The p53 tumor suppressor is one of the most frequently mutated genes in human cancers and 
its role as regulator of the cell cycle has been well characterized (see reviews (91;92).  p53 
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responds to many cellular stresses such as DNA damage, nucleotide depletion, oncogenic 
stress and hypoxia by activating transcription of downstream genes, resultant in cell cycle 
arrest, senescence, and apoptosis (93-96).  It is evident that p53 protects genetic stability by 
arresting the cell cycling at checkpoints and responding to the cellular stress either by 
allowing the cell to repair damage or triggering apoptosis or senescence pathways that 
eliminate the propagation of mutations and instabilities.  However, the role of p53 in 
preventing aneuploidy is less well characterized.  There is a large body of evidence 
correlating aneuploidy in tumors with p53 loss (see review by Hainaut and Hollstein(97)).  
Studies in p53-null mice also support a p53-aneuploidy connection as both tissues and 
tumors from these mice have higher levels of aneuploidy than wildtype counterparts (98;99).  
Work in cell culture systems has found that E1A and H-Ras infected p53-null MEFs and B-
cells overexpressing MDM2, the primary regulator of p53, have increased chromosome 
instability (100-102). However, these are not direct evidence of loss of p53 aiding in the 
development of aneuploidy.  Also, human cells with p53 removed by homolgous 
recombination remain diploid (103).  While p53 inactivation may not cause aneuploidy, it is 
likely that functional p53 may help protect from the development of aneuploidy.   
p53 likely prevents aneuploidy development through several mechanisms.  Mice with 
the R175P-p53 mutation, which eliminates p53 dependent apoptosis but retains cell cycle 
arrest, develop primarily diploid tumors, versus aneuploid tumors found in p53 null mice 
(104).  Follow up work demonstrated that combining this mutation with p21 inactivation 
reverted the tumor development and chromosome instability back to similar to that of p53-
null (105).  This suggests that at least in mice, the cell cycle regulatory functions of p53 may 
be more important than apoptotic pathways.  To support this, aneuploidy is increased in cells 
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with inhibited DNA fragmentation, regardless of p53 status (106).  In addition, p21, the main 
p53 dependent cell cycle regulator is strongly involved with preventing two of the key means 
of aneuploidy development, polyploidy and centrosome amplification.   
The development of polyploidy is believed to be a precursor event in the development 
of tumors and p53 is a key regulator of ploidy.  p53-null tetraploid mouse mammary 
epithelial cells undergo transformation after carcinogen treatment at a much higher rate than 
diploid controls, providing evidence that p53 protects against tumorigenesis resulting from 
increases in ploidy (107) and p53 promotes apoptosis in newly tetraploid cells (108).  Further 
evidence suggests that polyploidy is frequently a genetically unstable state and results in 
frequent aneuploidy, as polyploidy frequently precedes aneuploidy in tumorigenesis 
(17;18;109). Polyploidy can result either from endoreduplication, when cells replicate DNA 
but do not undergo cell division, or from cytokinesis failure.  Early studies initially identified 
p53 as part of a mitotic checkpoint, after the observation that p53-null cells continue through 
the cell cycle after blocking anaphase with spindle inhibitors (110).  Lanni and Jacks (1998) 
subsequently demonstrated that p53 null cells treated with spindle inhibitors arrest in mitosis 
after nocodazaole treatment, indicating a functional SAC, but reenter the cell cycle and 
replicate their DNA after exiting mitosis (111).  Further studies elucidated the mechanisms of 
the p53-dependent cell cycle arrest.  Blocking cell cleavage with dihydrocytochalasin B 
resulted in arrest at G1 in a p53 dependent manner, and failure to arrest resulted in 
aneuploidy development (112).  However, more recent evidence suggests that the checkpoint 
observed in these studies may be sensing spindle damage or mitotic irregularities and not 
ploidy, as cell fusion experiments which increased ploidy without damage to the centrosomes, 
chromosomes, or spindle does not activate G1 arrest (113).  Regardless of the activating 
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mechanism for arrest it is likely that p53 promotes chromosome stability and prevents 
transformation.   
In addition to aneuploidy, centrosome aberrations are frequently seen in human 
tumors (reviewed in (114).  Like DNA, centrosomes are replicated in a semi-conservative 
manner, with each cell receiving one centrosome that must be duplicated before underoing 
mitosis.  Centrosomes act as the microtubule organizing centers during mitosis. Achieving 
biorientation of the chromosomes requires 2 centrosomes at opposite ends of the cells, as 
multiple centrosomes greatly increase the chance of missegregating chromosomes and the 
development of aneuploidy (see Figure 3).  Early studies of p53 null mice revealed frequent 
centrosome abnormalities, suggesting p53 was involved in centrosome regulation (115).  
Further work revealed that centrosome duplication is controlled by CDK2/cyclinE, which is 
in turn regulated by the p53 transcriptional target p21 (116).  p53 has also been shown to 
localize at centrosomes, and likely has a trans-activation independent role in centrosome 
regulation as well.  Mutations in either the centrosome localization domain or transactivation 
domain of p53 only partially represses centrosome duplication, but both mutations together 
almost completely disrupt centrosome duplication (117).  Thus loss of p53 could result in 
increased aneuploidy as a result of centrosome amplification. 
While there is no direct evidence for p53 involvement in maintaining mitotic arrest, 
p53 may still regulate events related to chromosome segregation.  Mitotic arrest by the 
spindle checkpoint has been demonstrated to be necessary for activation of the p53 
dependent G1 tetraploidy checkpoint (118), linking p53 activation to SAC function.  In 
addition, while p53 may not be necessary for activation of the SAC, it may be important for 
responding to disruption of SAC genes.  Burds et al. (2006) demonstrated that Mad2-null cell 
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lines could be generated when combined with deletion of p53, likely due to reduction in p53 
mediated apoptosis after chromosome missegregation (119).  It has previously been 
demonstrated that knockdown of the spindle checkpoint protein Bub1 leads to slower 
population doubling times and increased senescence (90).  Finally, BubR1 has been linked to 
the DNA damage response in mitosis and the regulation of p53 levels in mitosis, while p53 
has also been found to regulate BubR1, with increased expression of BubR1 stabilizing 
karyotypes in late passage p53-null MEFs (71;120).  While there may not be conclusive 
evidence of a role for p53 in the spindle checkpoint function, it is clear that p53 and the 
spindle checkpoint both play important roles in protecting genomic stability. 
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Figure Legends 
Figure 1. Stages of mitosis with expression of mitotic cyclins.  The transition from G2 into 
mitosis is marked with falling cyclin A levels and rising cyclin B.  Cyclin B levels remain 
high until entry into anaphase, when it is degraded by APC.   
 
Figure 2. Spindle assembly checkpoint inhibition of APC/Cdc20.  Attachment of spindle 
fibers to kientochores and biorientation of the chromosomes satisfies the spindle checkpoint, 
allowing the breakdown of cohesions by APC/Cdc20. 
 
Figure 3.  Multiple centrosomes in a p53-null cell.  DAPI-stained chromosomes are blue, 
microtubules stained with ß-tubulin are red. 
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CHAPTER 2 
IMPAIRED BUB1 FUNCTION IN VIVO COMPROMISES TENSION-DEPENDENT 
CHECKPOINT FUNCTION LEADING TO ANEUPLOIDY AND TUMORIGENESIS 
 
Proper chromosome segregation is critical at every cell division to prevent aneuploidy, 
a condition associated with aggressive cancer, birth defects and infertility (reviewed in 1). 
The spindle assembly checkpoint (SAC) is a major guardian of mitotic fidelity. The SAC 
works as a checkpoint and timing mechanism to delay sister chromatid separation and 
anaphase onset until all chromosomes achieve bipolar attachment to microtubules at the 
metaphase plate.  The SAC can be activated by lack of kinetochore-microtubule attachment 
or loss of tension on the kinetochore microtubules, thus allowing it to respond to the major 
types of aneuploidy-generating defects that arise during mitotic progression (reviewed in (1-
3)).  The SAC blocks anaphase entry by inhibiting the APC/Cdc20 complex, a multisubunit 
ubiquitin ligase that induces anaphase by promoting proteosomal degradation of mitotic 
substrates. The mechanism of APC/Cdc20 inhibition by the SAC is multi-tiered, including 
inhibitory binding of SAC components Mad2 and/or BubR1 to cdc20, and Bub1-mediated 
inhibitory phosphorylation of APC/Cdc20 (3). Distinct inhibitory pathways may be activated 
by different conditions (e.g. loss of microtubule attachment vs loss of tension), although it 
remains unclear whether the different regulatory mechanisms function in separate pathways 
or as part of an integrated signaling system. The 
relative contributions of each mechanism to overall mitotic fidelity are also not well 
understood.  The spindle checkpoint machinery is encoded by a core group of genes 
originally identified in Saccharomyces cerevisiae, including Mad1-3, Bub1, Bub3, and Mps1. 
Yeasts lacking core SAC components grow normally under unperturbed conditions, yet 
display increased rates of chromosome missegregation and are unable to grow in the 
presence of spindle poisons such as nocodazole (4-6).  Studies of SAC function in mammals 
have been limited by the fact that murine null mutations in core SAC components including 
Bub3, Mad1, Mad2, and BubR1, cause very early embryonic lethality, precluding analysis of 
embryonic fibroblasts or later developmental stages in null mutants(7-10). However, mouse 
embryonic fibroblasts (MEFs) heterozygous for Mad2, Bub3 and BubR1 displayed 
haploinsufficiency, resulting in higher levels of mitotic abnormalities (9;11;12). Furthermore, 
while heterozygous animals were viable in each case, they displayed increased age-related 
spontaneous (11) or carcinogen-induced (9;13) tumorigenesis. Mice with a hypomorphic 
BubR1 allele that reduced BubR1 levels to ~11% of wt were viable, but displayed cellular 
senescence, growth retardation and progeroid features without a significant increase in tumor 
formation (12). These studies indicate that the SAC is essential for early embryonic 
development in mammals, but that the phenotypes obtained from incomplete SAC 
impairment may vary across a broad range depending on the depleted component and the 
degree of depletion. SAC components may also have SAC-independent functions that 
contribute to the observed phenotypes in some cases (14-16).   
  Despite its identification as a core spindle checkpoint component in yeasts, the 
functions of Bub1 have not been fully elucidated. Bub1 is a serine/threonine kinase that 
localizes to kinetochores during mitosis and mediates efficient kinetochore localization of 
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other SAC components. Bub1 deletion in yeasts causes high chromosome missegregation 
rates under normal growth conditions, in addition to lethality under perturbed conditions (4-
6). Studies in vertebrate systems have been confined to biochemical and cell culture models, 
and have produced sometimes conflicting results about Bub1 roles in mitotic regulation. 
Bub1 is essential for spindle checkpoint activity in Xenopus extracts, and the bulk of this 
activity requires the N-terminus, with minor requirements for the C-terminal kinase functions 
(17;18).  In cultured mammalian cell lines, Bub1 reduction via RNAi produced conflicting 
results.  In one case, Bub1 was surprisingly dispensable for SAC function, but was required 
for chromosome congression (15). An independent study found that Bub1 was required for a 
functional SAC response to nocodazole, while confirming the role in chromosome 
congression (16). These differences are difficult to reconcile, but may stem from distinct 
levels of Bub1 depletion and/or differences in cell lines used for the studies.  More recent 
studies have revealed a role for Bub1 in meiotic and mitotic sister chromatid cohesion via 
interaction with shugoshin (19;20). Finally, compromised Bub1 function has been indirectly 
associated with tumorigenesis, indicating an important need to understand the molecular 
links associated with Bub1 function, mitotic regulation and tumor suppression(21-24). 
To better understand Bub1 functions and the consequences of Bub1 loss in vivo, we 
developed a conditional Bub1 mutation in mice. We report here that this mutation is 
hypomorphic, causing a severe reduction in Bub1 levels. Mice homozygous for the Bub1 
hypomorph mutation are viable on mixed 129P2/B6 and FVB genetic backgrounds, but 
display high rates of tumorigenesis. The mutant phenotype is more severe on a C57Bl/6J 
background, where homozygous mutants die perinatally. In MEFs, Bub1 mutation causes 
high rates of chromosome missegregation and aneuploidy, accompanied by growth defects 
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and premature senescence. Surprisingly, the spindle checkpoint is functional in Bub1 mutant 
MEFs, though the checkpoint response to Taxol is significantly impaired. BubR1 kinetochore 
localization is markedly reduced in Bub1-mutant MEFs, consistent with the conclusion that 
Bub1 plays a key role in a BubR1-dependent tension-sensitive SAC response.  These 
findings indicate that Bub1 is critical for proper progression through mitosis and that defects 
in Bub1 signaling cause severe defects ranging from early lethality to tumorigenesis.  
 
METHODS 
Bub1 gene targeting and mice. Bub1 genomic BAC clones were isolated from a 129SvEv 
library by hybridization screening and subsequent PCR verification. The bacterial strain 
EL350 (44) was used for “recombineering” to subclone a 13 kb fragment encompassing 
Bub1 exons 1-6 into a pUC19-based plasmid including a PGK-thymidine kinase gene (a gift 
of R. Thresher, UNC animal models core facility). A loxP site was inserted in intron 1 by 
recombineering a loxP-flanked zeocin cassette, followed by Cre-mediated cassette removal 
in EL350. A loxP and FRT-flanked neomycin resistance cassette was subsequently inserted 
into intron 3. The targeting vector was linearized and used for gene targeting in E14 ES cells 
(129P2/OlaHsd strain). ES cell targeting was verified by PCR and Southern blot, and 
correctly targeted clones were injected into C57Bl/6J blastocysts for chimera generation. 
Chimeric males were bred to C57Bl/6J females and germline transmission of the Bub1neo 
allele was verified by PCR. The BubΔ2-3 and Bub1f alleles were generated by crossing the 
Bub1neo allele with an X-linked CMV-Cre strain (45). BubΔ2-3 viability phenotypes were 
studied on three genetic backgrounds: 129/B6 (F2-F4), B6N4+ and FVBN7+. For the FVB 
studies, the Bub1∆2-3 allele was independently derived from the Bub1neo allele by crossing 
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(FVBN5)Bub1neo/+ animals to an FVB-β-Actin-Cre deleter strain. The Cre transgene was 
removed by segregation prior to intercrossing BubΔ2-3/+ animals.  MEF studies were 
performed with MEFs derived from embryos on the C57Bl/6J background (B6N4+). All 
mice were maintained according to the Institutional Animal Care and Use Committee 
(IACUC) at the University of North Carolina at Chapel Hill. 
 Bub1GT8 allele.  Bub1 gene-trapped ES cell clone XG453 was obtained from Bay Genomics. 
The gene trap is produced by a splice-acceptor-β-geo cassette within Bub1 intron 7.  XG453 
ES cells were injected into C57Bl/6J blastocysts and resulting chimeras were bred to 
C57Bl/6J females and screened for germline transmission by PCR. Animals used in 
experiments reported here were backcrossed 1-2 generations to C57Bl/6J. All animal 
experiments were approved by the Institutional Animal Care and Use Committee of the 
University of North Carolina at Chapel Hill. 
 
Cell Culture 
Mouse embryonic fibroblast lines were generated from e13.5-e14.5 using standard protocols.  
MEFs were cultured at 5% CO2 in media containing DMEM-H with 10% fetal bovine serum, 
2 mM glutamine, 50 ug/ml penicillin, 50 ug/ml streptomycin, and  55 µM 2-mercaptoethanol 
and were passaged every 2 days by plating 500,000 viable cells.  All experiments with MEFs 
were performed at passage 3-4, unless otherwise stated.  Growth curves were generated by 
counting total number of viable cells at each passage..  Drug treatments were used at the 
following concentrations: nocodazole (Sigma-Aldrich) 200 ng/ml;paclitaxel (Sigma-
Aldrich)1µM; MG132 (Calbiochem),10 µM. 
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Spindle Checkpoint Analysis 
Asynchronously growing MEFs were treated with 200 ng/ml nocodazole for indicated times, 
trypsinized, fixed for 20 minutes in 1% formaldehyde, spun down and resuspended in 70% 
cold ethanol.  For flow cytometry, cells were stained with anti-phospho-Histone H3 (Upstate 
Biotechnology) at 1:500 and Alexafluor 488 (Invitrogen) at 1:1000, followed by Propidium 
Iodide.  30,000 Cells were analyzed on a Becton Dickinson FACscan and the number of 
phospho-Histone H3 postive cells measured as a percentage of total cells 
 
Immunofluroescence 
 Coverslips were fixed in 2% formaldehyde, permeablized in PBS + 0.5% Triton X-100, and 
washed in PBS.  After blocking 30’ in PBS-TX plus 5% NFDM or BSA, coverslips were 
incubated overnight with primary antibodies. Antibodies were used at the following 
concentrations: rabbit anti-Phospho-Histone H3 1:500 (Upstate Biotechnology), 1:250 anti-β-
tubulin (Tub2.1, Sigma-Aldrich), Sheep anti-Bub1 1:500 (Steve Taylor), rabbit anti-Mad2 
1:500 (E.D. Salmon),  rabbit anti-BubR1 (BD Biosciences),  human anti-centromere, 1:500 
(ACA, Antibodies Incorporated.). Following washes with PBS-TX, coverslips were 
incubated 1 hour with  appropriate secondary antibodies (Alexafluor 488 or 594) at 1:500 in 
PBS-TX plus 5% NFDM or BSA, washed with PBS-TX, DAPI stained and mounted with 
Flouromount G (Electron Microscopy Sciences).  Analysis was carried out on a Leica 
DMRXA microscope.  See Supplemental data for specifics on kinetochore localization 
methods. 
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Karyotyping 
MEFs at passage 5 were treated with Karyomax® colcemid (Invitrogen) for 4 hours, 
trypsinized, resuspended in warm 75mM hypotonic KCl buffer, and incubated for 20 minutes.  
Cells were washed at least four times in Carnoy’s buffer before being resuspended in fresh 
Carnoy’s fix and dropped onto cold, ethanol washed slides and DAPI stained.  Images of 
single cell spreads were acquired on a Leica DMRXA microscope with a 63x objective.  
Chromsomes from distinct individual cells were counted, with chromosome numbers greater 
than 70 for a single cell being discarded as endoreduplication. 
 
Senescence assay 
MEFs grown on coverslips at indicated passages were fixed in 1% formaldeyde and 0.1% 
glutaraldehyde for 5 minutes before being treated overnight (14-18 hours) in SA beta-gal 
buffer (See Dimiri et.al.(46)).  Cells were counterstained with DAPI and cells staining 
positive for senescence were counted as a percentage of total cells.   
 
Western Blotting and Immunoprecipitation 
Sub-confluent MEFs were treated with 200 ng/ml nocodazole for 6 hours, lysed in modified 
RIPA buffer., separated by SDS-page and transferred to nitrocellulose membranes.  
Membranes were blocked 30-60’ in PBS+ 0.1% Tween-20 (PBS-T) with 5% Non-fat dried 
milk (NFDM) and incubated overnight at 4C with anti-Bub1 1:1000 (a kind gift from Steve 
Taylor), diluted in PBS-T+ 5% NFDM.   For immunopreciptation, plates of sub-confluent 
cells were treated with 200 ng/ml nocodazole for 6 hours and 10µm MG132 for 2 hours cells 
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were collected from plates as above.  500 ug total protein was incubated overnight at 4º C 
with 50 µl anti-Bub1 sera (28).  
 
Results 
Generation of the Bub1∆2-3 allele.  We generated a conditional mutation of the murine Bub1 
gene by homologous recombination in ES cells. Based on available sequence information, 
deletion of exons 2 and 3 was predicted to cause a null allele by creating a frameshift early in 
exon 4, leading to a premature stop codon in exon 6 (Figure 1A). The targeting construct was 
designed with a loxP site in intron 1, and a loxP-flanked neomycin resistance cassette in 
intron 3, thus allowing deletion of exons 2 and 3 by Cre mediated recombination 
(Supplementary Figure S1A.  Correctly targeted ES cell clones were used to generate 
chimeric founders that transmitted the Bub1neo allele through the germline (Supplementary 
Figure S1B).  Bub1neo/+ mice were crossed to a germline Cre deleter strain (see Materials and 
methods) to produce the Bub1 floxed allele (Bub1f) by removal of the neomycin resistance 
cassette, and the Bub1Δ2-3 allele by removal of the neo cassette and exons 2 and 3.  Bub1neo/+, 
Bub1f/+ and Bub1∆2-3/+ mice are viable and fertile.  Genotypes were confirmed by PCR 
(Supplementary Figure S1C).   
 
Bub1∆2-3/∆2-3 survival is dependent on genetic background.  Homozygous deletion of 
spindle checkpoint genes Mad2, Bub3, and BubR1 in mice causes embryonic lethality at 
e4.5-7.5 during rapid expansion of the inner cell mass(7;8;10).  Bub1∆2-3/+ mice were 
intercrossed to test whether Bub1 loss also causes early embryonic lethality. Surprisingly, 
Bub1∆2-3/∆2-3 animals were obtained at near Mendelian ratios from intercrosses on a mixed 
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129P2/B6 genetic background (Table 1). However, intercrosses performed after backcrossing 
4 or more generations to C57Bl/6J yielded live Bub1∆2-3/∆2-3 animals at only 20% of expected 
Mendelian frequency (Table 1), and nearly all live-born (B6)Bub1∆2-3/∆2-3 mice died 
perinatally. (B6)Bub1∆2-3/∆2-3 mice appeared to breathe and nurse normally, but displayed 
runting and failure to thrive in the early postnatal period. The average weight of Bub1∆2-3/∆2-3 
animals was 1.19 ± 0.06 g versus 1.41 ± 0.13 g for WT (p < 0.01) on day of birth.  To date, 
only 2 homozygous animals survived to weaning at 21 days.  To determine when the 
remaining 80% of (B6)Bub1∆2-3/∆2-3 mice die, embryos were generated from (B6)Bub1∆2-3/+ 
intercrosses at E13.5-14.5 and E17.5-18.5. At both E13.5-14.5 and E17.5-18.5, (B6)Bub1∆2-
3/∆2-3, (B6)Bub1∆2-3/+ and (B6)Bub1+/+ embryos were recovered at Mendelian ratios (Table 1).  
Histological analysis of sections from e14.5 and e18.5 whole embryos did not reveal any 
morphological defects (data not shown). Observations of cell death in the liver and the 
marked paleness of some (B6)Bub1∆2-3/∆2-3 embryos led us to perform cell blood count (CBC) 
analysis on blood from e18.5 embryos, revealing mild anemia and leukocytosis.  In summary, 
(B6)Bub1∆2-3/∆2-3 mice displayed perinatal lethality of unknown cause, while Bub1∆2-3/∆2-3 
animals were viable on a 129/B6 mixed background. We also derived the Bub1∆2-3 allele on 
an FVB genetic background in which (FVB)Bub1∆2-3/∆2-3 animals are obtained at Mendelian 
ratios (Table 1). Together, these results indicate that that the phenotype of the Bub1∆2-3 allele 
is modified by the genetic background. The perinatal lethal phenotype of (B6)Bub1∆2-3/∆2-3 
animals is similar to that of mice harboring a hypomorphic mutation of the BubR1 spindle 
checkpoint gene (12), as well as mice with mutations of DNA damage genes such as BRCA2 
(25).  This observation, coupled with results from inactivation of other spindle checkpoint 
genes in mice, strongly suggests that the Bub1∆2-3 allele retains partial function. 
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The Bub1∆2-3 allele is hypomorphic.  The recovery of viable Bub1∆2-3/Δ2-3 mice suggested the 
Bub1∆2-3 allele may be hypomorphic rather than null. To test this hypothesis, we obtained 
mice harboring a Bub1 gene-trap allele with a beta-geo cassette and splice acceptor inserted 
in intron 7 (see Materials and methods).  Intercrosses of Bub1gt8/+ animals revealed a likely 
maternal defect in breeding, as very few live mice of any genotype were recovered from 
these crosses, and 90% of embryos were resorbed by e14.5.  Crosses of Bub1∆2-3/+ females 
with Bub1gt8/+ males demonstrated that compound heterozygous (Bub1∆2-3/gt8) animals were 
absent before e11.5 (Table 1).  Since the genetic background in these experiments is mixed 
129/B6, a background that supported survival of Bub1∆2-3/∆2-3 animals, the failure to recover 
compound heterozygous animals at mid-gestation is strong genetic evidence that the Bub∆2-3 
allele is hypomorphic, as the Bub1gt8 allele is apparently more severe. 
To determine the nature of the Bub1∆2-3 mutation, we first analyzed mRNA 
production in embryonic fibroblasts (MEFs) from E14.5 embryos. Quantitative RT-PCR (not 
shown) and northern hybridization analysis demonstrated equivalent RNA levels in Bub1+/+ 
and Bub1∆2-3/Δ2-3 MEFs (Supplementary Figure S2A ). Bub1∆2-3/Δ2-3 MEFs expressed a single 
Bub1 mRNA that was smaller than the wt mRNA, consistent with the deletion of exons 2 and 
3.  cDNA from Bub1∆2-3/∆2-3 MEFs was cloned and sequenced, demonstrating that the mRNA 
produced from the mutant allele is spliced from exon 1 to exon 4 as predicted 
(Supplementary Figure S2B). No novel alternatively spliced RNAs were detected by 
Northern or RT-PCR analyses using various primer sets across the Bub1 mRNA sequence 
(data not shown). Together, these data suggest that residual function of the Bub1∆2-3 allele, if 
any, must be derived from the ∆2-3 mutant mRNA. 
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Analysis of the predicted mRNA from the Bub1∆2-3 allele suggested two alternative 
possibilities for mutant protein expression:  (1) an ATG codon 5’ to the published start codon 
could produce a protein that is out of frame until reaching the exon 1- exon 4 splice, but in-
frame thereafter (aa 77 to aa 1058 ), and/or (2) translation from in-frame internal ATG’s 
present in exon 4 or beyond producing N-terminal truncations (aa 103, or 173 to 1058; Figure 
1A).  These ATG’s are not in Kozak consensus sequences but could still give rise to 
protein(26). To distinguish these possibilities, we analyzed protein from Bub1∆2-3/∆2-3 MEFs 
by Western blot using an antibody raised against Bub1 aa 336-489 (27).  No Bub1 protein 
was detected in extracts from Bub1∆2-3/∆2-3 MEFs, while Bub1∆2-3/+ and Bub1+/+ MEFs 
expressed a Bub1 protein of expected size (Figure 1B).  Likewise, no protein was detected in 
129/Bl6 Bub1∆2-3/∆2-3 MEFs or tissues (data not shown). Titration of WT cell lysate 
demonstrated the sensitivity of Bub1 detection to be 5% of normal endogenous levels (Figure 
1C) indicating that the Bub1∆2-3 allele disrupts production of the wild-type Bub1 protein and 
that any protein produced from the mutant allele must be produced at less than 5% of wild 
type levels.  Immunoprecipitation (IP)-Western blot analysis using an antibody recognizing 
residues 1-331 of the Bub1 protein for IP (28) and the antibody recognizing residues 336-489 
for Western analysis (27), detected a mutant-specific  band of ~115 kDa in Bub1∆2-3/∆2-3 and 
Bub1∆2-3/+ samples (Figure 1D).  This protein could be produced by translation from either an 
upstream or downstream ATG, and thus lacks at least the N-terminal 73 aa of Bub1. Thus, 
the phenotypes observed in Bub1∆2-3/∆2-3 mice and MEFs could be due to the lack of a critical 
N-terminal Bub1 domain, severely diminished protein levels, or both.     
Bub1 and BubR1 kinetochore localization are reduced in Bub1∆2-3/∆2-3 MEFs.  Bub1 
localizes to kinetochores in response to lack of spindle attachment and/or tension, and is 
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required for efficient localization of other spindle checkpoint proteins that mediate the 
spindle checkpoint activity (15). The domain required for Bub1 kinetochore localization is 
encoded by exon 8, and is thus likely to be included in the protein encoded by the Bub1∆2-3 
allele (29). Nevertheless, Bub1 staining at kinetochores of Bub1∆2-3/∆2-3 MEFs was only 2% 
of wt (Figures 2A), consistent with severely reduced total levels of mutant Bub1 protein. 
In cultured cell lines Bub1 is required for efficient kinetochore localization of other 
spindle checkpoint proteins such as Mad2 and BubR1 in response to SAC activation (15;30). 
SAC activation can be modeled experimentally by treating cells with nocodazole (which 
causes a loss of kinetochore-spindle attachment and tension) or Taxol (which disrupts tension 
forces between kinetochores while leaving attachments intact).  Using immunofluorescence, 
we examined the Mad2 and BubR1 at kinetochores of Bub1∆2-3/∆2-3 MEFs after nocodazole or 
Taxol treatment. However, significant cell-to-cell variation and high background with ACA 
staining precluded accurate measurement (Supplemental Figure S3).  To control for the 
variance, cells singly stained with Mad2 or BubR1 were counted and classified according to 
level of kinetochore localization (Figure 2B): “++++” bright kinetochore staining; “+++” dim 
above background kinetochore staining,; “++” kinetochore staining at punctate background 
levels, “+” no kinetochore staining. Using this stratification, a clear difference in kinetochore 
localization of BubR1, but not Mad2, was detected in response to both nocodazole and Taxol.  
Mad2 staining was clearly evident at kinetochores (++++ or +++) in 100% of Bub1+/+ and 
93% of Bub1∆2-3/∆2-3 MEFs after nocodazole treatment.  Mad2 localization after Taxol 
treatment is comparably weak in both wildtype and mutant cells (Figure 2C).  In contrast, 
BubR1 kinetochore localization was greatly reduced in Bub1∆2-3/∆2-3 cells when treated with 
nocodazole (44% of cells had clear kinetochore localization versus 99% of wildtype, p<0.05) 
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or Taxol (15% versus 83%, respectively, p<0.05) (Figures 2D).  These results indicate that 
Bub1 is necessary for proper BubR1 kinetochore localization in response to lack of 
kinetochore-microtubule attachment and particularly to the lack of microtubule tension. 
 
Bub1∆2-3/∆2-3 MEFs exhibit a defective spindle checkpoint, chromosome segregation 
errors, and increased aneuploidy.  Kinetochore localization of SAC genes Mad2 and 
BubR1 has previously been speculated to be necessary for SAC function. The reduced 
BubR1 kinetochore localization in Bub1∆2-3/∆2-3 MEFs suggested that these cells may have a 
defective SAC response. We tested spindle checkpoint responses of Bub1∆2-3/∆2-3, Bub1∆2-3/+ 
and WT MEFs by measuring mitotic indeces [percent positive phospho-histone H3 (pH3)] 
after treatment with nocodazole or Taxol.  Bub1+/+, Bub1∆2-3/+, and Bub1∆2-3/∆2-3 MEFs all 
showed an increased mitotic index by 12 hours after nocodazole addition compared to 
untreated cultures, indicating that each genotype retains at least partial SAC function in 
response to spindle ablation (Figure 3A).  Nocodazole-treated Bub1∆2-3/+ and Bub1∆2-3/∆2-3 
cultures contained only modestly lower indexes (5.8% and 7% respectively) than the Bub1+/+ 
cultures (8.9%).  This result contrasts with reported results from MEFs heterozygous for a 
null mutation in Bub3 or a hypomorphic mutation of BubR1, which show a severely impaired 
arrest in response to nocodazole treatment (9;12).  Likewise, there was no increase in 
premature sister chromatid separation (PSCS) after treatment with colcemid (2.5% in Bub1∆2-
3/Δ2-3 vs 1.5% in Bub1+/+), another microtubule depolymerising agent.  In contrast to 
nocodazole treatment, Bub1∆2-3/∆2-3 MEFs did display a severe SAC defect in response to 
Taxol treatment (mitotic index 3.5% for Bub1∆2-3/Δ2-3 vs 8% for Bub1+/+; Figure 3A). These 
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data suggest that reduced protein levels and/or N-terminal deletion of Bub1 is more 
detrimental to the response to loss of tension than loss of attachment. 
The primary role of the spindle checkpoint is to aid proper segregation of the 
chromosomes by delaying anaphase until all chromosomes are attached and under tension by 
spindle fibers.  Loss of the spindle checkpoint has been linked to increased aneuploidy in 
several models of spindle checkpoint loss (9;12).  To test whether relaxation but not 
complete abrogation of the spindle checkpoint can increase aneuploidy under normal growth 
conditions, we determined the chromosome counts in metaphase spreads from Bub1 mutant 
and wild type MEFs.  Seventy-six percent of metaphases from Bub1∆2-3/∆2-3 MEFs were 
aneuploid, compared to 9% of wildtype and 23% of Bub1∆2-3/+ metaphases (Figure 3B). Most 
of the aneuploid cells showed gain or loss of only 1-2 chromosomes. These high levels of 
aneuploidy represent an extreme level of chromosome instability, indicating that Bub1 is 
essential for proper chromosome segregation under unperturbed growth conditions.  
While the aneuploidy in Bub1∆2-3/∆2-3 MEFs could be due to a relaxed spindle 
checkpoint, Bub1 has also been implicated in proper chromosome congression (i.e. the 
movement of chromosomes to the metaphase plate) (15;16).  To test whether Bub1 mutant 
MEFs congress chromosomes properly, synchronized MEFs were treated with the 
proteasome inhibitor MG132 as cells were entering mitosis.  Inhibiting the proteasome 
blocks securin and cyclin B degradation, preventing the separation of sister chromatids at the 
metaphase plate and stopping mitosis in metaphase. Defects in chromosome congression are 
detected by an increase in chromosomes that have not aligned at the metaphase plate. 
Consistent with previous RNAi studies (15;16), MG132-treated Bub1∆2-3/∆2-3 MEFs 
demonstrated an increase in chromosome congression defects, with 19.6% of mutant versus 
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5.7% of WT MEFs displaying uncongressed chromsomes (Figure 3C).  This result supports 
the conclusion that Bub1 plays a role in chromosome congression and suggests that defective 
congression may contribute to the extreme aneuploidy of Bub1∆2-3/∆2-3 MEFs. 
Uncongressed chromosomes should trigger a SAC response, delaying anaphase onset 
until congression is complete and kinetochores are under tension. We reasoned that the 
reduced sensitivity of the SAC response in Bub1∆2-3/∆2-3 MEFs may allow cells to enter 
anaphase despite the presence of one or more unattached or mono-oriented kinetochores, 
resulting in daughter cells with gain or loss of 1-2 chromosomes. This model predicts that 
unperturbed cells should have high rates of anaphase lagging chromosomes. Indeed, analysis 
of unperturbed Bub1∆2-3/∆2-3 MEFS during anaphase revealed that 47% of Bub1∆2-3/∆2-3 MEFs 
in anaphase had one or more lagging chromosomes, compared to only 9% of wt and 8% of 
heterozygotes (Figure 3D). Taken together, these results suggest that the extreme aneuploidy 
of Bub1∆2-3/∆2-3 MEFs is caused by a combination of defects in chromosome congression and 
SAC activation. 
 
Bub1∆2-3/∆2-3 MEFs are growth impaired with high rates of senescence.  High levels of 
aneuploidy in BubR1 hypomorphic animals and MEFs correlated with growth impairment 
and high levels of senescence (12). Furthermore, a recent study indicated that RNAi 
knockdown of Bub1 in primary human fibroblasts resulted in increased senescence (31). We 
determined growth and senescence rates in Bub1∆2-3/Δ2-3 MEFs to assess whether similar 
phenotypes occur in this system. WT and heterozygous cultures grew at similar rates, with 
expected decreases in cell accumulation at higher passages due to senescence (32), while 
Bub1∆2-3/∆2-3 MEFs grew much more slowly (Figure 4A). To ascertain the cause of the growth 
 44
differences, we assessed levels of apoptosis and senescence.  Bub1∆2-3/Δ2-3 MEFs did not 
show increased apoptosis relative to WT and heterozygous cells as measured by annexin 5 
staining (data not shown).  However, senescence-associated beta-galactosidase assays 
revealed that Bub1∆2-3/∆2-3 MEFs had a significant increase in senescence compared to 
wildtype MEFs at passage 3 (9.1% versus 3.1) and passage 5 (15.4% versus 4.4%) examined 
(Figure 5B and C).  The percentage of BrDU incorporating cells was also lower in Bub1∆2-
3/∆2-3 MEFs, consistent with the increase in senescent cells (not shown).  Bub1∆2-3/∆2-3 MEFs 
did not show marked increases in the DNA damage marker phospho-H2AX (3.1% vs 2.6% in 
WT MEFs; Figure 5D), indicating that DNA breaks did not contribute significantly to the 
senescent phenotype. These results indicate that the high levels of chromosome 
missegregation and aneuploidy in Bub1∆2-3/Δ2-3 cells trigger growth impairment via premature 
senescence. 
 
Impaired Bub1 function predisposes to increased tumorigenesis.  Aneuploidy arising 
from spindle checkpoint impairment or other defects has long been hypothesized to 
contribute to tumor formation. In support of this hypothesis, most heterozygous mouse 
spindle checkpoint mutants generated to date have shown modest increases in spontaneous 
and/or carcinogen-induced tumor formation (11;11-13;33). However, some evidence 
suggests that extreme aneuploidy may inhibit tumorigenesis (12;34). To determine if Bub1 
impairment contributes to tumor formation, cohorts of (129/B6)Bub1∆2-3/∆2-3 and controls 
were aged to 2 years. Approximately 76% of (129/B6)Bub1∆2-3/∆2-3 mice developed tumors 
by 23-25 months, compared to 42% of (129/B6)Bub1∆2-3/+ (p <0.05) and ~28% of 
(129/B6)Bub1+/+ animals (p<0.05) (Figure 5A)  As in aging wild type mice, the majority of 
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(129/B6)Bub1∆2-3/∆2-3 tumors were of liver origin and occurred at an increased frequency. 
Importantly, Bub1 mutation also broadened the tumor spectrum.  Lung tumors appeared in 
16 % (4 of 25) of (129/B6)Bub1∆2-3/∆2-3 mice  while no lung tumors were found in wild type 
littermate controls (Figure 5B).  While a significant increase in spontaneous tumors was not 
observed in the Bub1 (129/B6)Bub1∆2-3/+ cohort, a lung and brain tumor were observed, 
suggesting a possible change in tumor spectrum. These data indicate that Bub1 is a low 
penetrance tumor suppressor, likely with significant quantitative effects based on the genetic 
modification of phenotypes in distinct genetic backgrounds. Together with the results from 
Bub1∆2-3/∆2-3 MEFs, these data indicate that chromosome missegregation defects leading to 
aneuploidy in cells of Bub1 mutant mice drive postnatal developmental defects ranging from 
lethality to tumor formation depending on the associated genetic context. 
 
Discussion 
We have probed the functions of the mammalian mitotic regulator Bub1 by generating a 
hypomorphic mutation (Bub1∆2-3) in mice that lacks part of an N-terminal conserved domain 
implicated in spindle checkpoint function in yeast. In addition, the protein is expressed at 
severely diminished levels, yet retains sufficient function to support development to birth or 
adulthood, depending on the genetic context.  In the C57Bl6/J background homozygous 
mutant mice die perinatally with a “failure-to-thrive” phenotype, while FVB and mixed 
129P2/C57Bl6/J backgrounds support survival to late adulthood.  However, these mice 
develop a high incidence of cancers compared to wildtype littermates solidifying a role for 
impaired Bub1 function in tumorigenesis.   
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Bub1∆2-3 was characterized as a hypomorphic mutant by demonstrating that  
compound heterozygotes with a gene-trapped allele, Bub1gt8, die by E11.5. Indeed, two 
contemporary reports demonstrate that Bub1 null mutants arrest by E7.5 (35;35;36), 
consistent with the early embryonic lethality previously described for homozygous null 
mutants of the SAC genes Mad2, BubR1 and Bub3 (7;8;10). Based on the proposed Bub1 
ATG translation start site, the Bub1∆2-3 mutation was designed to produce a severely 
truncated protein lacking the kinase domain and expected to be non-functional.  Analyses of 
the mRNA expressed in mutant MEFs indicate that the transcript lacking exons 2 and 3 is 
expressed at normal levels. IP-Western analysis of nocodazole-arrested MEFs identified a 
unique protein in Bub1∆2-3/+ and Bub1∆2-3/∆2-3 MEFs that is approximately 5 kDa smaller than 
wt Bub1 and present at less than 5% of WT levels. Thus, the mutant Bub1 protein appears to 
be produced by translation from an alternative ATG, the most likely of which would give rise 
to an N-terminal truncation starting in exon 4 that retains the C-terminal kinase domain and 
the kinetochore binding domain.  The N-terminal domain of Bub1 is highly conserved in 
nearly all species but its function is still largely unknown.  In fission yeast, checkpoint 
activity and kinetochore localization were mapped to residues 28-160, while mammalian 
Bub1 residues 200-300 were found to be required for SAC function and kinetochore 
localization (6;29).  Because the mutant protein is expressed at such low levels, the current 
studies cannot distinguish whether impaired function results from deletion of a critical N-
terminal function, insufficient protein or both. Nonetheless, this mutant provides a tool for 
probing of the effects of reduced Bub1 function in cells and during embryonic and adult 
development. 
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Bub1 in mitotic checkpoint regulation.  MEFs derived from mutant and wildtype littermate 
embryos were used to assess the cellular phenotypes associated with impaired Bub1 function.  
A recent RNA interference study in cell lines questioned a role for mammalian Bub1 in SAC 
function (15), while a distinct study found that Bub1 depletion ablated the SAC (16). We 
show here that, despite undetectable levels of Bub1 binding at kinetochores, Mad2 is able to 
localize at kinetochores in Bub1∆2-3/Δ2-3 MEFs, which arrest in mitosis when treated with 
nocodazole.  These surprising results indicate that very little Bub1 is required for SAC 
activity in response to microtubule ablation in MEFs. Perera et al (36) recently found that 
Bub1-null MEFs do not show a sustained arrest after treatment with nocodazole, while 
Jeganathan et al. (35) showed that MEFs with ~20% of WT Bub1 activity arrest for a shorter 
duration than WT MEFs in nocodazole. The distinct methodologies employed (duration of 
mitotic arrest vs mitotic index) make it difficult to directly compare these results to ours and 
could be responsible for the discrepancy.  However, this inconsistency raises the possibility 
of a scenario where we have underrepresented the amount of Bub1∆2-3 protein that is 
expressed and are primarily observing the effects of the N-terminal deletion of the allele.    
Nevertheless, our results are supported by previous findings with Bub1 siRNA which found 
that only 5% of endogenous levels could support a mitotic arrest with spindle ablation 
(15;16).  These results together are consistent with a model in which a small amount of Bub1 
is sufficient to arrest cells in response to spindle ablation.  This contrasts with the 
haploinsufficiency of SAC function in MEFs heterozygous for Bub3 or hypomorphic for 
BubR1, which show very little mitotic arrest after nocodazole treatment (9;12).   
In contrast to Mad2, BubR1 kinetochore localization is reduced in Bub1∆2-3/Δ2-3 MEFs 
in response to nocodazole and further reduced after Taxol treatment. A similar reduction in 
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BubR1 kinetochore localization was recently observed in Bub1 null and hypomorph MEFs, 
providing a strong consensus that Bub1 is critical for BubR1 localization (35;36). Previous 
kinetochore localization studies suggest that BubR1 is responsive to changes in tension, 
while Mad2 binds kinetochores in response to attachment failure(37). The inhibition of 
APC/cdc20 in response to nocodazole may be due to integration of signals from both 
pathways (as evidenced by strong localization of both BubR1 and Mad2 with nocodazole 
treatment) while Taxol may only trigger the BubR1-dependent pathway.  While we see a 
reduction in BubR1 kinetochore localization after nocodazole treatment, the presence of 
substantial Mad2 at kinetochores in addition to reduced amounts of BubR1 is apparently 
sufficient for responding to loss of kinetochore-microtubule attachment.  Although Bub1 was 
previously shown to be necessary for efficient localization of both Mad2 and BubR1 to 
kinetochores, our data suggest that Bub1 is more critical in the tension-sensitive BubR1 
signaling pathway than in attachment sensing.  
 We show here that Bub1∆2-3/Δ2-3 MEFs rapidly develop a high frequency of 
aneuploidy that is likely explained by a weakened SAC response. Nocodazole and Taxol 
treated Bub1∆2-3/Δ2-3 MEFs have a reduced mitotic index relative to wt cells; yet, these assays 
are relatively crude and may not accurately measure weakened signaling capacity. A more 
sensitive test of SAC function comes when most chromosomes achieve bipolar attachment 
and tension, as the remaining signal from even a single unattached kinetochore must be 
sufficient to block anaphase onset until attachment and tension are achieved(38;39). Under 
these conditions, insufficiency of SAC components may impair the SAC enough to allow 
anaphase onset, resulting in lagging chromosome(s).  The high frequency of Bub1∆2-3/Δ2-3 
cells with lagging chromosomes, coupled with the fact that only 1 or 2 such chromosomes 
 49
are observed in most cells, suggest that chromosome missegregation in Bub1∆2-3/Δ2-3 cells is 
triggered by a defect in sensing minor, rather than catastrophic, mitotic aberrations.  Bub1 
has also been reported to play a role in chromosome congression and regulation of sister 
chromatid cohesion (15;16;19;20). We observed an increase in chromosome congression 
errors in Bub1∆2-3/Δ2-3 MEFs, suggesting that this mechanism may contribute to the mitotic 
errors in these cells. However, the percentage of cells with obvious congression errors was 
low relative to the percentage with lagging chromosomes, suggesting that congression errors 
are unlikely to account for the full extent of missegregation observed. Moreover, non-
congressed chromosomes should invoke a SAC arrest under normal conditions. Therefore, 
we argue that the mitotic defects in Bub1∆2-3/Δ2-3 MEFs are a consequence of impairment in 
both chromosome congression and SAC signaling.  
A large body of evidence indicates that cellular senescence suppresses cellular 
proliferation in response to DNA damage and/or oncogene activation. Here, we show that 
Bub1∆2-3/Δ2-3 MEFs are significantly growth impaired and produce high levels of premature 
senescence. This effect was less severe in Bub1∆2-3/+ MEFs, which also displayed lower 
levels of aneuploidy. Thus, a major consequence of impaired Bub1 function and resulting 
chromosome segregation errors appears to be permanent cell cycle arrest. Increased 
senescence was also observed in BubR1 hypomorph mice (12), which also display high rates 
of aneuploidy. Furthermore, aneuploid yeast were recently shown to display impaired growth 
and metabolic changes accompanied by evidence of protein degradation and folding distress 
(40). Thus, it is possible that the increased metabolic demand of extra chromosomes taxes the 
cellular machinery, causing a stress response that triggers senescence. Aneuploidy may also 
trigger stress responses by causing imbalances in signaling pathways.  
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Bub1 and tumor suppression.  Aneuploidy has long been associated with cancers, raising 
the hypothesis that spindle checkpoint impairment may predispose to tumorigenesis (41-43). 
Indeed, the presence of Bub1 mutations in human colon cancer cell lines (21) and murine 
lymphomas (22), fueled this hypothesis.  Here, we demonstrate a causal relationship between 
impaired Bub1 function and predisposition to cancer.  When analyzed in a background 
permissive to survival, impaired Bub1 function predisposed to a higher frequency and 
expanded spectrum of tumors relative to wildtype littermates.  Tumors arose in aging mice, 
indicative of a low penetrance effect, consistent with the notion that non-catastrophic rates of 
aneuploidy can produce tumorigenic chromosomal imbalances.  Mice heterozygous for a null 
mutation of other SAC genes also resulted in increased tumor incidence, either spontaneously 
(Mad1 (33), Mad2 (11), Cenp-E (34)) or after carcinogen treatment (BubR1 (13) and Bub3 
(9)).  The recent work of Jeganathan et. al.(35) showed an increasing tumor incidence with 
progressive loss of Bub1, reaching  55% in mice with ~20% of endogenous Bub1 levels.  The 
higher tumor incidence (76%) in our model correlates with the further reduction in Bub1 
levels to less than 5% and the corresponding increase in mitotic abnormalities. A severe 
hypomorphic allele of BubR1 caused only a modest increase in tumorigenesis; however 
animals aged prematurely potentially confounding the quantitative assessment of tumor 
incidence (12). CENP-E haploinsufficiency, which also causes severe aneuploidy, was 
recently shown to have either protective or tumorigenic effects, depending on the genetic and 
environmental context (34). Thus, the influence of mitotic infidelity on tumor formation 
appears to be dependent on the cellular and genetic context and likely reflects a quantitative 
trait. The level of mitotic disruption may be critical for tumor formation, with high levels of 
chromosome missegregation incompatable with cell survival or activating tumor suppression 
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pathways such as senescence.  Future study of the hypomorphic Bub1∆2-3 mutation in the 
context of an allelic series with other available Bub1 mutations, in addition to alterations in 
senescence pathway factors such as p53 should provide valuable insight into to the 
mechanistic relationship between mitotic aberration, chromosome instability and cancer. 
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Figure Legends 
Figure 1. Bub1 gene disruption.  (A) The BubΔ2-3 allele removes a portion of the N-terminal 
conserved domain. Top. Schematic of Bub1 protein domains and corresponding exons. 
Bottom. Possible protein products produced from the BubΔ2-3 allele.  (B) Western blot 
analysis of endogenous Bub1 protein in MEFs of indicated genotypes. No protein is detected 
from BubΔ2-3/Δ2-3 cells. GapDH was used as a loading control. (C) Titration of lysate from 
Bub1+/+ MEFs indicating that the Bub1 antibody detects 5% of endogenous levels. (D) 
Immunoprecipitation-Western blot. Arrow indicates a novel polypeptide detected in lysates 
from cells harboring the Bub1Δ2-3 allele. 
 
Figure 2. Bub1 and BubR1 are reduced at kinetochores in Bub1Δ2-3/Δ2-3 MEFs. (A) Left. 
Quantitation of Bub1 levels at kinetochores, normalized to ACA (centromere marker). Right. 
Representative Bub1, ACA and merged images from wt and Bub1 mutant MEFs.  (B) 
Representative images illustrating staining level classifications used in quantitations for C-F. 
(C) Mad2 kinetochore localization after treatment with nocodazole (left) and Taxol (right). 
Bars indicate percentage of cells of each class depicted in B. (D) BubR1 kinetochore 
localization after treatment with nocodazole (left) and Taxol (right).  N=50 cells each from 
three individual experiments for C and D. 
 
Figure 3. Bub1Δ2-3/Δ2-3 MEFs have reduced spindle checkpoint activity and increased mitotic 
abnormalities (A) Accumulation of mitotic (phosphohistone H3-positive) cells after 
nocodazole treatment (left) and Taxol treatment (right). (B) Incidence of aneuploid cells in 
P5 MEFs. (C) Quantitation of uncongressed chromsomes after 3 hr MG132 treatment with 
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epresentative image of a metaphase nucleus with an uncongressed chromosome. (D) 
Quantitation of anaphase lagging chromosomes with representative image.  Graphs in A, C 
and D represent mean and SEM of 3 independent experiments for each genotype, with at 
least 10000 cells analyzed per genotype per experiment in A , and at least 50 cells per 
genotype per experiment for C and D. “*” indicates p< 0.05. 
 
Figure 4. Bub1Δ2-3/Δ2-3 MEF cultures have reduced growth and increased senescence.  (A) 
Total cell numbers accumulated at indicated passages. 500,000 cells were plated at each 
passage (lower markers) and total cells counted upon passage 2 days later (upper markers). 
(B) Representative acidic ß-gal staining (blue) of a BubΔ2-3/Δ2-3 culture. (C) Senescent cells as 
a percentage of total cells at passages 3, 5, and 7. N= 3 independent experiments per 
genotype. (D) Bub1Δ2-3/Δ2-3 MEFs do not demonstrate increased DNA damage. Percentage of 
cells positive for phospho-H2AX immunostaining.  Teal bars indicate duplicate control 
samples treated with doxorubicin to induce DNA damage.  “*” indicates p< 0.05 and error 
bars indicate SEM. 
 
Figure 5. Tumor incidence and spectrum is increased with Bub1 mutation.  (A) Tumor 
incidence in Bub1Δ2-3/Δ2-3 mice and controls (B) Tumor spectrum. 
 
Supplemental Figure 1. Targeting of the Bub1 locus.  (A)  Targeting strategy for producing 
the Bub1neo, Bub1f, and BubΔ2-3  alleles.  LoxP sites are indicated by red triangles and FRT 
sites by green ovals.  (B) A Southern blot confirming integration of the targeting cassette in 
ES cells.  (C) PCR products for Bub1 alleles. 
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 Supplemental Figure 2.  RNA and protein expression from the BubΔ2-3 allele.  (A) A northern 
blot on RNA from Bub1+/+ and Bub1Δ2-3/Δ2-3 MEFs, showing bands of expected sizes.  (B) 
Sequence of cDNA from Bub1Δ2-3/Δ2-3 MEFs showing splicing directly from exon 1 to 4.  (C)  
The full length western blot from Figure 1B.  (D)  The full length IP-western blot from 
Figure 1D. 
 
Supplemental Figure 3.  Kinetochore localization of Mad2 and BubR1.  (A) Left. 
Quantitation of Mad2 levels at kinetochores, normalized to ACA (centromere marker). Right. 
Representative Mad2, ACA and merged images from wt and Bub1 mutant MEFs.  (B) Left. 
Quantitation of BubR1 levels at kinetochores, normalized to ACA (centromere marker). 
Right. Representative BubR1, ACA and merged images from wt and Bub1 mutant MEFs.  (C)  
Representative images of Mad2 (left) and BubR1 (right) localization to kinetochores in the 
absence of ACA. 
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Table 1. Viability of Bub1 mutant mice 
Genotype Background Live Births E18.5 E14.5 
Bub1Δ2-3/+ x Bub1Δ2-3/+     
+/+ 68 26 17 
Δ2-3/+ 109 39 34 
Δ2-3/Δ2-3 
 
B6 
 18*(2)# 22 18 
+/+ 33   
Δ2-3/+ 76   
Δ2-3/Δ2-3 
 
FVB 
 35   
+/+ 162  15 
Δ2-3/+ 353  23 
Δ2-3/Δ2-3 
 
B6/129 
 96  14 
Bub1Δ2-3/+ x Bub1gt8/+     
+/+ 40  10 
Δ2-3/+ 30  27 
gt8/+ 21  10 
Δ2-3/gt8 
 
B6/129 
 
0  0 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 57
Figure 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 58
Figure 2 
 
 
 
 59
  Figure 3 
 
 
 60
Figure 4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 61
Figure 5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 62
Supplemental Figure 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 63
Supplemental Figure 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 64
Supplemental Figure 3 
 
 
 
 
 
 
 
 65
Reference List 
 
 (1)  Lew DJ, Burke DJ. The spindle assembly and spindle position checkpoints. Annu 
Rev Genet 2003;37:251-82. 
 (2)  Cleveland DW, Mao Y, Sullivan KF. Centromeres and kinetochores: from 
epigenetics to mitotic checkpoint signaling. Cell 2003 Feb 21;112(4):407-21. 
 (3)  Musacchio A, Salmon ED. The spindle-assembly checkpoint in space and time. Nat 
Rev Mol Cell Biol 2007 May;8(5):379-93. 
 (4)  Bernard P, Hardwick K, Javerzat JP. Fission yeast bub1 is a mitotic centromere 
protein essential for the spindle checkpoint and the preservation of correct ploidy 
through mitosis. J Cell Biol 1998 Dec 28;143(7):1775-87. 
 (5)  Warren CD, Brady DM, Johnston RC, Hanna JS, Hardwick KG, Spencer FA. Distinct 
chromosome segregation roles for spindle checkpoint proteins. Mol Biol Cell 2002 
Sep;13(9):3029-41. 
 (6)  Vanoosthuyse V, Valsdottir R, Javerzat JP, Hardwick KG. Kinetochore targeting of 
fission yeast mad and bub proteins is essential for spindle checkpoint function but not 
for all chromosome segregation roles of bub1p. Mol Cell Biol 2004 
Nov;24(22):9786-801. 
 (7)  Dobles M, Liberal V, Scott ML, Benezra R, Sorger PK. Chromosome missegregation 
and apoptosis in mice lacking the mitotic checkpoint protein Mad2. Cell 2000 Jun 
9;101(6):635-45. 
 (8)  Kalitsis P, Earle E, Fowler KJ, Choo KH. Bub3 gene disruption in mice reveals 
essential mitotic spindle checkpoint function during early embryogenesis. Genes Dev 
2000 Sep 15;14(18):2277-82. 
 (9)  Babu JR, Jeganathan KB, Baker DJ, Wu X, Kang-Decker N, van Deursen JM. Rae1 
is an essential mitotic checkpoint regulator that cooperates with Bub3 to prevent 
chromosome missegregation. J Cell Biol 2003 Feb 3;160(3):341-53. 
 (10)  Wang Q, Liu T, Fang Y, Xie S, Huang X, Mahmood R, et al. BUBR1 deficiency 
results in abnormal megakaryopoiesis. Blood 2004 Feb 15;103(4):1278-85. 
 (11)  Michel LS, Liberal V, Chatterjee A, Kirchwegger R, Pasche B, Gerald W, et al. 
MAD2 haplo-insufficiency causes premature anaphase and chromosome instability in 
mammalian cells. Nature 2001 Jan 18;409(6818):355-9. 
 (12)  Baker DJ, Jeganathan KB, Cameron JD, Thompson M, Juneja S, Kopecka A, et al. 
BubR1 insufficiency causes early onset of aging-associated phenotypes and infertility 
in mice. Nat Genet 2004 Jul;36(7):744-9. 
 66
 (13)  Dai W, Wang Q, Liu T, Swamy M, Fang Y, Xie S, et al. Slippage of mitotic arrest 
and enhanced tumor development in mice with BubR1 haploinsufficiency. Cancer 
Res 2004 Jan 15;64(2):440-5. 
 (14)  Fisk HA, Mattison CP, Winey M. Human Mps1 protein kinase is required for 
centrosome duplication and normal mitotic progression. Proc Natl Acad Sci U S A 
2003 Dec 9;100(25):14875-80. 
 (15)  Johnson VL, Scott MI, Holt SV, Hussein D, Taylor SS. Bub1 is required for 
kinetochore localization of BubR1, Cenp-E, Cenp-F and Mad2, and chromosome 
congression. J Cell Sci 2004 Mar 15;117(Pt 8):1577-89. 
 (16)  Meraldi P, Sorger PK. A dual role for Bub1 in the spindle checkpoint and 
chromosome congression. EMBO J 2005 Apr 20;24(8):1621-33. 
 (17)  Sharp-Baker H, Chen RH. Spindle checkpoint protein Bub1 is required for 
kinetochore localization of Mad1, Mad2, Bub3, and CENP-E, independently of its 
kinase activity. J Cell Biol 2001 Jun 11;153(6):1239-50. 
 (18)  Chen RH. Phosphorylation and activation of Bub1 on unattached chromosomes 
facilitate the spindle checkpoint. EMBO J 2004 Aug 4;23(15):3113-21. 
 (19)  Tang Z, Sun Y, Harley SE, Zou H, Yu H. Human Bub1 protects centromeric sister-
chromatid cohesion through Shugoshin during mitosis. Proc Natl Acad Sci U S A 
2004 Dec 28;101(52):18012-7. 
 (20)  Kitajima TS, Hauf S, Ohsugi M, Yamamoto T, Watanabe Y. Human Bub1 defines the 
persistent cohesion site along the mitotic chromosome by affecting Shugoshin 
localization. Curr Biol 2005 Feb 22;15(4):353-9. 
 (21)  Cahill DP, Lengauer C, Yu J, Riggins GJ, Willson JK, Markowitz SD, et al. 
Mutations of mitotic checkpoint genes in human cancers. Nature 1998 Mar 
19;392(6673):300-3. 
 (22)  Lee H, Trainer AH, Friedman LS, Thistlethwaite FC, Evans MJ, Ponder BA, et al. 
Mitotic checkpoint inactivation fosters transformation in cells lacking the breast 
cancer susceptibility gene, Brca2. Molecular Cell 1999;4(1):1-10. 
 (23)  Jaffrey RG, Pritchard SC, Clark C, Murray GI, Cassidy J, Kerr KM, et al. Genomic 
instability at the BUB1 locus in colorectal cancer, but not in non-small cell lung 
cancer. Cancer Res 2000 Aug 15;60(16):4349-52. 
 (24)  Shigeishi H, Oue N, Kuniyasu H, Wakikawa A, Yokozaki H, Ishikawa T, et al. 
Expression of Bub1 gene correlates with tumor proliferating activity in human gastric 
carcinomas. Pathobiology 2001;69(1):24-9. 
 67
 (25)  Friedman LS, Thistlethwaite FC, Patel KJ, Yu VP, Lee H, Venkitaraman AR, et al. 
Thymic lymphomas in mice with a truncating mutation in Brca2. Cancer Res 1998 
Apr 1;58(7):1338-43. 
 (26)  Meijer HA, Thomas AA. Control of eukaryotic protein synthesis by upstream open 
reading frames in the 5'-untranslated region of an mRNA. Biochem J 2002 Oct 
1;367(Pt 1):1-11. 
 (27)  Taylor SS, Hussein D, Wang Y, Elderkin S, Morrow CJ. Kinetochore localisation and 
phosphorylation of the mitotic checkpoint components Bub1 and BubR1 are 
differentially regulated by spindle events in human cells. J Cell Sci 2001 Dec;114(Pt 
24):4385-95. 
 (28)  Cowley DO, Muse GW, Van Dyke T. A dominant interfering Bub1 mutant is 
insufficient to induce or alter thymic tumorigenesis in vivo, even in a sensitized 
genetic background. Mol Cell Biol 2005 Sep;25(17):7796-802. 
 (29)  Taylor SS, Ha E, McKeon F. The human homologue of Bub3 is required for 
kinetochore localization of Bub1 and a Mad3/Bub1-related protein kinase. J Cell Biol 
1998 Jul 13;142(1):1-11. 
 (30)  Meraldi P, Honda R, Nigg EA. Aurora kinases link chromosome segregation and cell 
division to cancer susceptibility. Curr Opin Genet Dev 2004 Feb;14(1):29-36. 
 (31)  Gjoerup OV, Wu J, Chandler-Militello D, Williams GL, Zhao J, Schaffhausen B, et al. 
Surveillance mechanism linking Bub1 loss to the p53 pathway. Proc Natl Acad Sci U 
S A 2007 May 15;104(20):8334-9. 
 (32)  Parrinello S, Samper E, Krtolica A, Goldstein J, Melov S, Campisi J. Oxygen 
sensitivity severely limits the replicative lifespan of murine fibroblasts. Nat Cell Biol 
2003 Aug;5(8):741-7. 
 (33)  Iwanaga Y, Chi YH, Miyazato A, Sheleg S, Haller K, Peloponese JM, Jr., et al. 
Heterozygous deletion of mitotic arrest-deficient protein 1 (MAD1) increases the 
incidence of tumors in mice. Cancer Res 2007 Jan 1;67(1):160-6. 
 (34)  Weaver BA, Silk AD, Montagna C, Verdier-Pinard P, Cleveland DW. Aneuploidy 
acts both oncogenically and as a tumor suppressor. Cancer Cell 2007 Jan;11(1):25-36. 
 (35)  Jeganathan K, Malureanu L, Baker DJ, Abraham SC, van Deursen JM. Bub1 
mediates cell death in response to chromosome missegregation and acts to suppress 
spontaneous tumorigenesis. J Cell Biol 2007 Oct 15;. 
 (36)  Perera D, Tilston V, Hopwood JA, Barchi M, Boot-Handford RP, Taylor SS. Bub1 
maintains centromeric cohesion by activation of the spindle checkpoint. Dev Cell 
2007 Oct;13(4):566-79. 
 68
 (37)  Skoufias DA, Andreassen PR, Lacroix FB, Wilson L, Margolis RL. Mammalian 
mad2 and bub1/bubR1 recognize distinct spindle-attachment and kinetochore-tension 
checkpoints. Proc Natl Acad Sci U S A 2001 Apr 10;98(8):4492-7. 
 (38)  Rieder CL, Cole RW, Khodjakov A, Sluder G. The checkpoint delaying anaphase in 
response to chromosome monoorientation is mediated by an inhibitory signal 
produced by unattached kinetochores. J Cell Biol 1995 Aug;130(4):941-8. 
 (39)  Rieder CL, Schultz A, Cole R, Sluder G. Anaphase onset in vertebrate somatic cells is 
controlled by a checkpoint that monitors sister kinetochore attachment to the spindle. 
J Cell Biol 1994 Dec;127(5):1301-10. 
 (40)  Torres EM, Sokolsky T, Tucker CM, Chan LY, Boselli M, Dunham MJ, et al. Effects 
of aneuploidy on cellular physiology and cell division in haploid yeast. Science 2007 
Aug 17;317(5840):916-24. 
 (41)  Kops GJ, Weaver BA, Cleveland DW. On the road to cancer: aneuploidy and the 
mitotic checkpoint. Nat Rev Cancer 2005 Oct;5(10):773-85. 
 (42)  Rajagopalan H, Lengauer C. Aneuploidy and cancer. Nature 2004 Nov 
18;432(7015):338-41. 
 (43)  Bharadwaj R, Yu H. The spindle checkpoint, aneuploidy, and cancer. Oncogene 2004 
Mar 15;23(11):2016-27. 
 (44)  Lee EC, Yu D, Martinez de Velasco J, Tessarollo L, Swing DA, Court DL, et al. A 
highly efficient Escherichia coli-based chromosome engineering system adapted for 
recombinogenic targeting and subcloning of BAC DNA. Genomics 2001 Apr 
1;73(1):56-65. 
 (45)  Su H, Mills AA, Wang X, Bradley A. A targeted X-linked CMV-Cre line. Genesis 
2002 Feb;32(2):187-8. 
 (46)  Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, et al. A biomarker that 
identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad 
Sci U S A 1995 Sep 26;92(20):9363-7. 
 
 
 
 
 
 
 
 
 
 
 
 69
CHAPTER 3 
TWO WRONGS DON’T MAKE A RIGHT: P53 INACTIVATION FAILS TO RESCUE 
PERINTAL LETHALITY IN MICE WITH A HYPOMORPIC ALLELE OF BUB1 
 
Chromosome instability during tumorigenesis was initially observed over a hundred 
years ago and is considered a hallmark of human cancers (1).  The gain or loss of 
chromosomes, tends to become more severe as tumors progress and further correlates with a 
poor patient prognosis (2).  However, it is not known whether aneuploidy contributes to 
tumor development or is merely a byproduct of general misregulation of the cell cycle that 
occurs during tumorigenesis.  There is considerable evidence for aneuploidy contributing to 
tumorigenesis: aneuploidy is present in many precancerous tissues (3), carcinogenen-treated 
animals frequently develop aneuploidy before tumor development (4;5), and aneuploidy 
precedes transformation after infection with SV40 tumor virus (6).  Aneuploidy may aid 
tumorigenesis by introducing rapid genetic change, but there is strong evidence that severe 
aneuploidy is a growth disadvantage by inducing senescence, apoptosis or mitotic 
catastrophe (7-9). 
A key mechanism for regulating the proper segregation of chromosomes is the 
spindle assembly checkpoint (SAC), which halts the progression of mitosis at metaphase 
until all chromosomes are attached to spindle fibers and bioriented (10;11).  The SAC is 
comprised of a core group of proteins (Bub1, Bub3, Mad1, Mad2, Mad3/BubR1, and MPS1) 
originally identified in Saccharomyces cerevisiae, but found to be highly conserved in all 
eukaryotes, that regulate the Anaphase Promoting Complex (APC) through inhibition of its 
specificity factor, Cdc20 (12-14). While not essential for viability during unperturbed growth 
in yeasts, most SAC genes appear to be essential in higher organisms, as germline 
inactivation of core spindle checkpoint components in nematodes (mdf1/Mad1, 
mdf2/Mad2, )(15) and flies (Bub1 and Bub3)(16;17) causes developmental lethality, 
although Mad2 is not essential in Drosophila (18).  Mouse models of core SAC genes have 
further demonstrated the essential nature of the spindle checkpoint with germline deletion of 
Mad1, Mad2, Bub1, Bub3 and BubR1 leading to massive cell death and embryonic loss by 
e5.5-8.5, a time during development when the inner cell mass (ICM) undergoes a series of 
very rapid cell divisions (19-22).  The core SAC genes also show increased tumor 
development with haploinsufficincy (Mad2, Mad1), hypomorphic alleles (Bub1), or 
carcinogen treatment (Bub3 and BubR1) (8;23-26).  It is clear that mitosis must be very 
tightly regulated to avoid tumor development, as there is evidence for both loss and gains in 
expression of mitotic regulators contributing to tumorigenesis (20;27-29).    
The Bub1 kinase is a core spindle checkpoint gene with multiple roles in mitotic 
regulation.  Required for efficient kinetochore localization of spindle checkpoint proteins, 
Bub1 also directly inhibits Cdc20-APC interaction via phosphorylation of Cdc20 (30-32).  
Initial work on Bub1 with in vitro studies or cell culture assays provided mixed evidence on 
whether Bub1 was required for spindle checkpoint arrest, suggesting that Bub1 may be 
necessary only for responding to loss of tension on spindle fibers or a weak checkpoint 
activation (30-34).  Subsequent studies in conditional or hypomorhpic MEFs demonstrate 
reduced duration of mitotic arrest with exposure to spindle poisons, although a hypomorphic 
allele with an N-terminal deletion resulted in a more severe defect in responding to loss of 
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tension than attachment (24).  Data from yeast, Xenopus extracts, and mammalian cells all 
reveal chromosome instability and aneuploidy with Bub1 loss and data from primary human 
fibroblasts and mouse embryonic fibroblasts (MEFs) demonstrate decreased proliferation 
with Bub1 loss and increased senescence. 
The tumor suppressor p53 is one of the most frequently mutated genes in human 
cancers and is critical for maintaining genetic stability.  p53 responds to wide range of 
cellular stresses such as DNA damage, oncogenic stress and nucleotide depletion by 
transcriptional activation of genes involved in DNA repair, cell cycle arrest, senescence and 
apoptosis (Reviewed in (35;36)).  While p53’s role in preventing genetic instability has been 
well defined, its role in chromosomal instability is less well characterized.  Aneuploidy 
coinciding with p53 loss in tumors is frequently observed, although as both aneuploidy and 
p53 loss are two of the most common events in tumorigenesis, this is not necessarily 
evidence of causation (2).  Tissues and cells from p53-null mice are highly anepoloid (37) 
and overexpressing MDM2 in B-cells (38) or expressing E1A and H-Ras in p53-null cells 
(39) result in increased chromosome instability.  Data from mice suggest that cell cycle 
control is more important for preventing aneuploidy as mice with a mutant allele of p53 
(R175P) that is able to regulate the cell cycle but not induce apoptosis develop primarily 
diploid tumors with a longer tumor latency than p53 null mice (40).  Combining this allele 
with loss of p21, a p53 dependent regulator of progression through G1, reverts the tumor 
latency and chromosomal instability to similar levels as p53 null animals, indicating an 
important role for cell cycle control in preventing accumulation of aneuploidy cells (41).  In 
addition to the G1 checkpoint, p53 also regulates duplication of the centrosomes, at least 
partially through p21 (42;43)  and loss of p53 leads to multiple spindle poles and associated 
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aneuploidy (37;44).  A p53 allele with a mutation in the centrosome localization domain only 
partially represses centrosome duplication and p53 with an inactive transactivation domain 
only partially represses centrosome duplication, but both mutations together almost 
completely disrupt centrosome duplication, evidence for a direct role of p53 at centrosomes 
as well as transcriptional activation (43). 
Early studies of p53 inactivation suggested a role for p53 in the mitotic checkpoint, as 
p53-null cells will reinitiate DNA synthesis after exposure to microtubule inhibitors (45).  
Subsequent work demonstrated that p53-null cells arrest in mitosis after exposure to the 
spindle poisons for the same duration as wildtype controls, but continue replicating their 
DNA, leading to a 8N and 16N cells, suggesting a role in averting polyploidy, but not in the 
SAC itself (46).  Further work identified a p53 dependent checkpoint for preventing 
proliferation of polyploidy cells, a cellular condition that frequently leads to aneuploidy.  The 
activating stimuli for this checkpoint is disputed as early work suggested arrest after 
development of polyploidy through cytokinesis failure, while more recent studies suggest 
p53 responds to spindle damage and not chromosome numbers (47-49).  Although p53 does 
not appear to be necessary for mitotic arrest, there may be a role for p53 in responding to loss 
of SAC failure.  Burds et al.(2006) demonstrated death of Mad2-null embryos could be 
delayed when combined with deletion of p53, indicating that cell death in Mad2-null 
embryos is at least partially p53-dependent (50).  Furthermore, shRNA mediated knockdown 
of Bub1 in primary human fibroblasts results in high levels of p53-dependent senescence 
(51). 
In our previous work we demonstrated that a hypomorphic allele of Bub1 (Bub1∆2-3) 
is perinatal lethal and this correlates with increased senescence and decreased growth rates in 
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MEFs.   In this follow up work, we report that p53 inactivation fails to rescue perinatal 
lethality observed in Bub1∆2-3/∆2-3 animals.  Bub1∆2-3/∆2-3;p53-/- MEFs have significant defects 
in growth rates despite displaying low levels of senescence and cell death.  Furthermore, p53 
status does not significantly impact spindle checkpoint function or chromosome segregation 
in Bub1∆2-3/∆2-3 MEFs. 
 
Methods 
Analysis of Mice.  Bub1Δ2-3+;p53+/- mice used for intercrosses in this study were generated 
by backcrossing Bub1Δ2-3/+ mice at least 6 generations onto C57/Bl6 and then breeding 
heterozygous females with C57/Bl6 congenic p53-/- males.  All mice were maintained 
according to the Institutional Animal Care and Use Committee (IACUC) at the University of 
North Carolina at Chapel Hill. 
 
Cell Culture.  Mouse embryonic fibroblast lines were generated from e13.5 using standard 
protocols.  MEFs were cultured at 5% CO2 in media containing DMEM-H with 10% fetal 
bovine serum, 2 mM glutamine, 50 ug/ml penicillin, 50 ug/ml streptomycin, and  55 µM 2-
mercaptoethanol and were passaged every 2 days by plating 1 million viable cells.  All 
experiments with MEFs were performed at passage 3-4, unless otherwise stated.  Growth 
curves were generated by counting total number of viable cells at each passage. Drug 
treatments were used at the following concentrations: nocodazole (Sigma-Aldrich) 200 
ng/ml;paclitaxel (Sigma-Aldrich)1µM. 
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Spindle Checkpoint Analysis.  Asynchronously growing MEFs were treated with 200 ng/ml 
nocodazole for indicated times, trypsinized, fixed for 3 minutes in 1% formaldehyde, spun 
down and resuspended in 70% cold ethanol.  For flow cytometry, cells were stained with 
anti-phospho-Histone H3 (Upstate Biotechnology) at 1:500 and Alexafluor 488 (Invitrogen) 
at 1:1000, followed by Propidium Iodide.  30,000 Cells were analyzed on a Becton 
Dickinson FACscan and the number of phospho-Histone H3 postive cells measured as a 
percentage of total cells 
 
Analysis of lagging chromosomes.  1.5X10^5 cells were grown overnight on acid-washed 
22 milimeter coverlslips.  Coverslips were fixed in 2% formaldehyde for 20’ and washed in 
PBS.  After blocking 30’ in PBS + 0.1% Triton X-100 with 5% non-fat dried mild (NFDM), 
coverslips were incubated overnight with primary antibodies. Antibodies were used at the 
following concentrations: rabbit anti-Phospho-Histone H3 1:500 (Upstate Biotechnology), 
1:250 anti-β-tubulin (Tub2.1, Sigma-Aldrich).  Following washes with PBS-TX, coverslips 
were incubated 1 hour with appropriate secondary antibodies (Alexafluor 488 or 594) at 
1:500 in PBS-TX plus 5% NFDM, washed with PBS-TX, DAPI stained and mounted with 
Flouromount G (Electron Microscopy Sciences).  Analysis was carried out on a Leica 
DMRXA microscope. 
 
Karyotyping.  MEFs at passage 5 were treated with Karyomax® colcemid (Invitrogen) for 4 
hours, trypsinized, resuspended in warm 75mM hypotonic KCl buffer, and incubated for 20 
minutes.  Cells were washed at least four times in Carnoy’s buffer before being resuspended 
in fresh Carnoy’s fix and dropped onto cold, ethanol washed slides and DAPI stained.  
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Images of single cell spreads were acquired on a Leica DMRXA microscope with a 63x 
objective and chromsomes from distinct individual cells were counted. 
Senescence assay. MEFs grown on coverslips at indicated passages were fixed in 1% 
formaldeyde and 0.1% glutaraldehyde for 5 minutes before being treated overnight (14-18 
hours) in SA beta-gal buffer (See Dimiri et.al.(52)).  Cells were counterstained with DAPI 
and cells staining positive for senescence were counted as a percentage of total cells.   
 
Results 
P53 loss does not rescue lethality in Bub1 hypomorphic mice.  We previously reported the 
characterization of a hypomorphic murine Bub1 allele, Bub1∆2-3, which was found to be 
perinatal lethal on a C57/B6 background but viable on mixed 129P2/B6 and FVB 
backgrounds.  MEFs homozygous for the Bub1∆2-3 allele were shown to have slower growth 
rates, high levels of senescence, and chromosome segregation errors (data not shown).  
Studies in primary human fibroblasts suggest that senescence associated with Bub1 knock 
down is due to the tumor suppressor p53 and loss of p53 has been shown to be capable of 
rescuing embryonic lethal murine knockouts that result in increased senescence (53-55).  To 
determine whether inactivation of p53 is capable of rescuing the perinatal lethality afflicting 
Bub1∆2-3 homozygous animals, we performed intercrosses with Bub1∆2-3;p53+/- animals 
(Table 1).  Consistent with previous results, there was substantial lethality with Bub1Δ2-3 
homozygozity, as only 1 of an expected 18 Bub1Δ2-3/Δ2-3,p53+/+ animals survived to weaning 
age at 21 days.  No Bub1Δ2-3/Δ2-3;p53-/- animals and 2 Bub1Δ2-3/Δ2-3;p53+/- mice were recovered, 
demonstrating that lethality associated with reduced Bub1 function is not dependent on p53.  
Embryonic litters examined at post-coital day 13.5 revealed that Bub1Δ2-3/Δ2-3;p53+/+, Bub1Δ2-
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3/Δ2-3;p53+/-, Bub1Δ2-3/Δ2-3;p53-/- animals were all recovered as expected.  Preliminary analysis 
of e18.5 embryos suggests lethality in Bub1Δ2-3/Δ2-3;p53-/- animals is perinatal (data not 
shown).  Interestingly, no live Bub1∆2-3/+;p53-/- females were recovered either, suggesting 
that combining Bub1 heterozygozity and p53 nullizygozity is lethal in females.  The lethality 
of female mice could be due to an increase in aneuploidy resulting in miscarriage of embryos 
or due an exacerbation of the exencephaly frequently seen in p53-null females (56).   
 
P53 does not rescue growth defects of Bub1 mutant MEFs.  To explore whether p53 loss 
affects the growth defects seen in Bub1∆2-3/∆2-3 mouse embryonic fibroblasts (MEFs), we 
generated MEF cultures from intercrosses of  Bub1∆2-3;p53+/- animals and compared growth 
rates of Bub1+/+;p53+/+, Bub1+/+;p53-/-, Bub1Δ2-3/Δ2-3;p53+/+, Bub1Δ2-3/Δ2-3;p53+/- and Bub1Δ2-
3/Δ2-3;p53+/+ MEF cultures.  We generated growth curves by counting viable cells at each 
passage (every two days), revealing that p53 loss increases growth rates in Bub1∆2-3/∆2-3;p53-/- 
cultures, but it does not completely ameliorate the effects of Bub1 loss (Figure 1A).  Bub1∆2-
3/∆2-3;p53-/- cells had similar growth rates to Bub1∆2-3/∆2-3;p53+/+ controls at early passages but 
stabilized at a slightly higher growth rate, while the Bub1∆2-3/∆2-3;p53+/+ cells lost 
proliferating cells at each passage by oxidative-stress induced senescence, a common 
phenomenon in MEFs (57).  We measured senescence in each genotype at passages three, 
five and seven by senescence associated ß-galalactosidase activity (SA ß-gal).  Bub1∆2-3/∆2-
3;p53+/+ and Bub1∆2-3/∆2-3;p53+/- cells had increased numbers of senescent cells at each 
passage (10% or higher) and the wildtype cells showed increased senescence by passage 7, 
but we observed only negligible positive staining in Bub1∆2-3/∆2-3;p53-/- and Bub1+/+;p53-/- 
cells at all passages, suggesting the growth defect associated with Bub1 loss is not primarily 
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due to p53-dependent senescence.  To determine if the growth differences could be due to 
apoptosis or mitotic catastrophe, we measured cell death by trypan blue staining at each 
passage.   There was a slight increase in cell death in the three Bub∆2-3/∆2-3 cultures compared 
to cells with wildtype Bub1 at passage 4 (3% versus 5%), but not at levels expected to result 
in the severe growth defect observed. These data suggest the growth defect caused by Bub1 
mutation does not appear to be caused by p53 induced senescence or cell death.  
 
P53 loss does not affect SAC function.  To assess the possible effects of combined Bub1 
and p53 inactivation on spindle checkpoint function we measured mitotic index after 
treatment with either nocodazole or Taxol as measure spindle checkpoint function.  Cells 
with a functional spindle checkpoint will arrest in mitosis after nocodazole or Taxol 
treatment, causing a buildup of mitotic cells.  The preponderance of evidence suggests p53 
does not have a role in the spindle checkpoint, but the recent finding that p53 is a 
transcriptional regulator of BubR1 suggests a link to SAC function (46;58).  We previously 
determined Bub1Δ2-3/Δ2-3 MEFs were deficient in their ability to arrest in mitosis after Taxol 
treatment and we demonstrate here that p53 status does not affect this as no significant 
differences in mitotic index are observed between Bub1∆2-3/∆2-3;p53+/+ (7.5%), Bub1∆2-3/∆2-
3;p53+/- (6.7%), or Bub1∆2-3/∆2-3;p53-/- (8.2%) MEFs.  There is likewise no significant 
difference between Bub1+/+;p53+/+ (13.2%) and Bub1+/+;p53-/- (14.0%) MEFs’ response to 
Taxol.  With nocodazole treatment, there was more variance between the genotypes tested at 
6 and 12 hours, but no significant differences in maximum mitotic index.  Mitotic indices 
peaked at 6 hours for Bub1∆2-3/∆2-3;p53+/+ (11.1%), Bub1∆2-3/∆2-3;p53+/- (10.2%), or Bub1∆2-
3/∆2-3;p53-/- (12.1%) and 12 hours for Bub1+/+;p53+/+ (13.6%) and Bub1+/+;p53-/- (15.6%) 
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MEFs.  While there was no difference in peak mitotic index, but there was a significant 
difference in mitotic indices at 48 hours.  Cells arrested in mitosis will eventually exit mitosis 
as cyclin B is degraded, a phenomenon known as mitotic slippage (59).  The percentage of 
mitotic cells in samples with wildtype or heterozygous p53 status had dropped to low levels 
at 48 hours while the Bub1∆2-3/∆2-3;p53-/- and Bub1+/+;p53-/- cultures had significantly higher 
levels of mitotic cells at 48 hours due to a failure of a p53-dependent checkpoint that arrests 
cells at G1 after polyploidization or mitotic failure (47-49).  DNA profiles reveal that 
cultures with wildtype p53 arrested primarily with 4N DNA contents, while Bub1∆2-3/∆2-3;p53-
/- and Bub1+/+;p53-/- MEFs continued cycling and by 48 hours the bulk of cells from these 
cultures had  8N DNA content and 16N populations as well (Figure 2C and D).  The 
polyploidy/spindle damage checkpoint has previously been determined to require spindle 
checkpoint function to activate G1 arrest after spindle damage (60).  However, our results 
demonstrate that Bub1 loss is not sufficient to jeopardize this checkpoint, as Bub1∆2-3/∆2-3 
MEFs arrest with 4N DNA content similar to wildtype cells after both Taxol and Nocodazole 
treatment.  To address whether there is difference in the duration of mitotic arrest, a factor 
which has previously been proposed as a determining factor in activation of the G1 
checkpoint, we measured the duration of mitotic arrest by live cell imaging in Bub1+/+ and 
Bub1∆2-3/∆2-3 MEF cultures.  Populations of cells were synchronized by serum starvation, 
released, and treated with either nocodazole or Taxol at 20 hours post-release and imaged for 
cell rounding as a measure of mitosis.  We found no significant difference in duration of 
mitotic arrest after nocodazole treatment, with Bub1+/+ MEFs having a mean arrest of 287 
minutes versus 255 minutes for Bub1∆2-3/∆2-3 cells.  Corresponding with the difference in 
mitotic index, Bub1∆2-3/∆2-3 mefs arrested for significantly less time in Taxol compared to 
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Bub1+/+ MEFs, with mean times of 96 and 182 minutes, respectively.  Thus while Bub1 
mutants had significantly shortened mitotic arrest in Taxol, it does not affect G1 arrest after 
exiting mitosis under perturbed conditions. 
 
No increases in chromosome missegregation and aneuploidy with combined p53 and 
Bub1 loss.  We previously demonstrated large increases in aneuploidy and chromosome 
missegregation in Bub1∆2-3/∆2-3 MEFs (data not shown).  Aneuploidy frequently develops 
with p53 functional loss, but the mechanisms have not been fully elucidated.  We assessed 
aneuploidy in MEFs to determine whether inactivation of p53 affects genomic stability and 
chromosome segregation after loss of normal spindle checkpoint function.  Bub1+/+;p53-/- 
MEFs had slightly higher levels of aneuploidy compared to Bub1+/+;p53+/+  cells, but we did 
not see a dramatic difference when p53 was lost in Bub1∆2-3/∆2-3 cells with Bub1Δ2-3/Δ2-
3;p53+/+, Bub1∆2-3/∆2-3;p53+/-, Bub1Δ2-3/Δ2-3;p53+/+ MEFs having 76%, 80%, and 77% 
aneuploidy respectfully (Figure 3A).  Likewise, we did not see an increase in chromosome 
segregation errors in Bub1∆2-3/∆2-3;p53-/- cells versus Bub1∆2-3/∆2-3;p53+/+.   These results 
demonstrate the aneuploidy phenotype caused by a Bub1 hypomorphic allele is not restricted 
by p53 activity. 
 
Discussion 
We have analyzed the combined effects of Bub1 mutation and p53 inactivation on animal 
viability and cellular characteristics by combining p53 deletion with a previously 
characterized hypomorphic allele of Bub1 (Bub1Δ2-3).  p53 has previously been shown to 
rescue embryonic lethality in several mouse knockout mice that suffer from increased 
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senescence, a phenotype observed in Bub1Δ2-3/Δ2-3 mice (53-55).  However, we do not see 
rescue of Bub1Δ2-3/Δ2-3 animals with p53 deletion and Bub1 heterozygozity appears to 
exacerbate lethality in p53 null females.  Bub1Δ2-3/Δ2-3;p53-/- MEFs continue to have severe 
growth defects despite a drastic reduction in senescence.  p53 inactivation does not affect 
spindle checkpoint function or development of aneuploidy in Bub1 Bub1Δ2-3/Δ2-3 MEFs.   
Viability is restored to Mad2-null blastocysts when p53 is deleted, indicating at least 
part of the cell death in early embryogenesis is p53 dependent (50) and inactivation of p53 in 
primary cells with reduced Bub1 expression eliminates senescence and partially restores 
growth rates (51).  Loss of p53 also rescues embryonic lethality in XRCC4 (54) null mice and 
∆11 BRCA1 (61) mutant mice.  Considering the increased senescence observed in Bub1∆2-
3/∆2-3 MEFs, we were surprised to find no rescue of Bub1∆2-3/∆2-3 animals with p53 
inactivation.  Lethality in Bub1∆2-3/∆2-3 mice occurs around birth with a failure-to-thrive 
phenotype that we had previously attributed to increased senescence and predicted would be 
rescued by p53 inactivation.  The cellular phenotype of Bub1Δ2-3/Δ2-3;p53-/- MEFs partially 
explains the failure of p53 loss to rescue Bub1Δ2-3/Δ2-3 animals.  Bub1Δ2-3/Δ2-3 MEFs were 
previously observed to have severe a growth defect that was at least in part attributed to 
increased senescence.  The senescence levels did not appear to completely account for 
differences in growth between Bub1+/+ and Bub1Δ2-3/Δ2-3 MEF cultures, but this was attributed 
to general underreporting by the SA-β-gal assay.  However, p53 deletion only partially 
rescued the growth defect of Bub1∆2-3/∆2-3;p53-/- MEFs, which grew slower than wildetype 
cells at early passages and grew slower than Bub+/+;p53-/- cells at all passages despite little 
observed senescence.  Increased cell death also did not appear to be a factor, suggesting 
Bub1 mutant MEFs are arresting by p53-independent means.  At this time we do not know 
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the means of cell cycle arrest in Bub1∆2-3/∆2-3 cells, but we can speculate.  SA-ß-gal staining 
measures lysosomal activity in a cell, which correlates with senescence due to increased 
lysosomal content found in senescent cells, but it is not known why senescent cells have 
more lysomomal content (62).  It is possible and even likely there is irreversible cell arrest 
that is not characterized by SA-ß-gal staining.  Quantitative measurements of other factors 
associated with senescence may help elucidate the mechanism of cell arrest, as well as 
analysis of p53-independent cell cycle arrest pathways.   
 
p53 response to aneuploidy.  The tumor suppressor p53 regulates the cell cycle checkpoints 
in responses to such stresses as DNA damage, oncogenic stress and many other signals, 
resulting in cell cycle arrest (transient or permanent) and apoptosis.  p53 is also critical for 
preventing the development of aneuploidy, as evidenced by increased aneuploidy in p53-null 
mice and associations with p53 inactivation and tumors (2;37).  However it is unknown 
whether p53 responds to ploidy changes or merely prevents them from developing by 
regulating centrosome duplication and spindle damage.  With this work we demonstrate that 
p53 does not dramatically impact aneuploidy development associated with Bub1 loss.  The 
high levels of senescence found in several mouse models with reduced SAC function (Bub1 
and BubR1 hypomorphs, Bub3/Rae1 heterozygozity) suggested an aneuploidy that results in 
senescence, but we have shown that inhibiting senescence through p53 deletion does not 
dramatically change the aneuploidy levels (8;63).  The high levels of aneuploidy (over 70%) 
in Bub1Δ2-3/Δ2-3 and BubR1h/h MEFs argue against a checkpoint that is capable of sensing 
small changes in ploidy.  However it was not known whether the preponderance of 1 and 2 
chromosome aneuploidies observed in these cells was specifically due to function (or lack) of 
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these alleles or because cells with larger loss of chromosomes are eliminated, either through 
senescence or cell death.  There may still be a mechanism for eliminating large scale 
aneuploidies, but it does not appear to be p53-dependent, although a larger sample size would 
increase our ability to detect small changes.  The high levels of aneuploidy in Bub1 mutant 
cells may have made it difficult to detect increases in aneuploidy from combined p53 loss, 
but there is another explanation for lack of a combined effect on aneuploidy raised by work 
with another Bub1 hypomorphic allele by the van Deursen lab.  Jeganathan et al. (2007) 
observed that when wildtype MEFs missegregated chromosomes, they frequently underwent 
apoptosis shortly thereafter while cells with reduced Bub1 function survived chromosome 
missegregation much more frequently, indicating Bub1 is involved in eliminating cells that 
have missegregated chromosomes (24).  If the induction of apoptosis after missegregating 
chromosomes is p53-dependent, then adding p53 inactivation to Bub1 loss is not likely to 
increase aneuploidy.  
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Figure Legends 
Figure 1. Bub1Δ2-3/Δ2-3;p53-/- MEF cultures display reduced growth despite low levels of 
senescence and cell death.  (A) Total cell numbers accumulated at indicated passages. 1 
million cells were plated at each passage and viable cells counted upon passage 2 days later. 
(B) Senescent cells as a percentage of total cells at passages 3, 5, and 7.  N=2 with at least 
500 cells assessed in each independent experiment (C)  Viability staining by percentage of 
cells staining positive for trypan blue at each passage.  Graphs in A and C represent mean 
and SEM of at least 5 independent experiments for each genotype. 
 
Figure 2. p53 status does not effect spindle checkpoint activity in Bub1Δ2-3/Δ2-3 MEFs. (A) 
Accumulation of mitotic (phosphohistone H3-positive) cells after nocodazole treatment   (B) 
Accumulation of mitotic (phosphohistone H3-positive) cells after Taxol treatment.  (C) DNA 
profiles of MEFs after Nocodazole treatment. (D) DNA profiles of MEFs after Nocodazole 
treatment. (E) Time arrested in mitosis after drug treatment.  Graphs in A and B represent 
mean and SEM of 3 independent experiments for each genotype, with at least 10000 cells 
analyzed per genotype per experiment. 
 
Figure 3. Aneuploidy and chromosome segregation errors are not increased with p53 
inactivation in Bub1Δ2-3/Δ2-3 MEFs. (A) Distribution of aneuploidy in P5 MEFs. (D) 
Quantitation of anaphase lagging chromosomes. 
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  Table 1  Viabilty of Bub1Δ2-3/p53KO mice 
Genotype F M e13.5 Expected 
Bub1+/+;p53+/+ 8 10 7 1:16 
Bub1+/+;p53+/- 15 17 8 1:8 
Bub1+/+;p53-/-  3 4 4 1:16 
Bub1Δ2,3/+;p53+/+  11 12 14 1:8 
Bub1Δ2,3/+;p53+/-  33 31 17 1:4 
Bub1Δ2,3/+;p53-/- 0 13 14 1:8 
Bub1Δ2,3/Δ2,3;p53+/+  0 2* 5 1:16 
Bub1Δ2,3/Δ2,3;p53+/-  1 1* 11 1:8 
Bub1Δ2,3/Δ2,3;p53-/-  0 0 6 1:16 
*Animals died before weaning at 21 days 
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CHAPTER 4 
CONCLUSIONS 
 
In recent years, the spindle assembly checkpoint (SAC) has developed as a keen area 
of interest in exploring the role of aneuploidy in tumorigenesis. Although Bub1 is a core 
member of the spindle assembly checkpoint, evidence has been mixed regarding its 
requirement for spindle checkpoint function.  We proposed to generate a knockout model of 
Bub1 to definitively assess the role of Bub1 in mitotic regulation as well as explore the 
impact of spindle checkpoint disruption on tumorigenesis.  Murine models of other spindle 
checkpoint genes demonstrated early embryonic lethality in null animals, thus a conditional 
allele was designed to allow either tissue specific or temporal deletion of Bub1, greatly 
expanding the utility of the allele.  Cre mediated excision of loxP flanked exons 2 and 3 was 
predicted to result in a severely truncated protein with splicing ocurring directly from exon 1 
to 4 resulted in a frameshift and termination of translation in exon 5.  However, limited 
survival of mice homozygous for germline deletion of exons 2 and 3 led us to suspect the 
Bub1∆2-3 allele was hypomorphic and not null.  Due to this possibility, we generated mice 
from ES cells with a gene trapped allele of Bub1, Bub1GT8, which has a B-Geo cassette and 
splice acceptor after exon 8. We intercrossed mice heterozygous for the Bub1∆2-3 and GT8 
alleles, but failed to generate compound heterozygous animals, suggesting the Bub1∆2-3 allele 
was less severe than the Bub1GT8 allele and thus not null.  We subsequently were able 
to detect a Bub1 protein expressed from the Bub1∆2-3 allele by IP Western, demonstrating 
production of a nearly full length protein at very low levels.  During the course of this work, 
two other labs generated null alleles of Bub1 and confirmed  its essential role  in embryonic 
development by observing death of  Bub1 null embryos before e8.5 (1;2) .  Though we 
initially sought to create null allele of Bub1 a hypomorphic allele has enabled us to assess 
Bub1’s role in SAC function, chromosome segregation and tumorigenesis.  
 
Bub1 and the spindle checkpoint.  Literature regarding the role of Bub1 in the spindle 
checkpoint has been controversial.  Various studies have found Bub1 to be either dispensable 
for SAC function, not essential for SAC functions, or required under specific activating 
stimuli.  Our work does not definitively answer questions regarding Bub1’s role in SAC 
function, but does highlight the importance of Bub1 for mitotic regulation.  In our study, we 
assessed spindle checkpoint function using two different methods-- assessing percentages of 
mitotic cells and timing mitosis by direct imaging of cell rounding after treatment with 
nocodazole or Taxol.  We observed a small difference in mitotic index after treatment with 
nocodazole, but a greater difference with Taxol treatment, confirming an earlier study 
suggesting Bub1 was primarily responsible for responding to loss of kinetochore-microtubule 
tension (3) .  While this coincides well with previous data  that suggested a role for Bub1 in 
responding to loss of tension, it conflicts with the more recent data from Bub1 null and 
hypomorphic MEFs generated by the Taylor and Van Deursen labs, both of which assessed 
SAC function by live cell imaging of cells with GFP-tagged chromosomes and found 
severely diminished mitotic arrest with monastrol and nocodazole treatment (1;2).  Mitotic 
index as a measure of SAC function provides a limited view, as the results can be 
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confounded by non-cycling cells and it is difficult to determine whether differences are due 
to the number of cells arrested or the duration of arrest.  Thus it is possible that the spindle 
checkpoint phenotype is the same in our models, but the method of assessing it gives a 
different readout.  Direct visualization of cells through live cell imaging provides a more 
sensitive assessment of SAC function by measuring the time individual cells spend in mitosis.   
Preliminary work measuring time in mitosis after drug treatment did not detect a significant 
difference with nocodazole treatment, but found that Bub1∆2-3/∆2-3 MEFs arrested for only 
half as long as Bub1+/+ controls treated with Taxol.  While the limits of our assay for cell 
rounding do not tell us precisely when mitosis ends, it does definitively tell us that Bub1∆2-
3/∆2-3 cells arrested for less time than wildtype cells after loss of tension on kinetechores with 
Taxol treatment, confirming a role for Bub1 in responding to loss of tension on kinetechores. 
Early reports produced conflicting data on whether Bub1 was essential for the spindle 
checkpoint.  HeLa cells with Bub1 knocked  down to 5% or below endogenous levels still 
had a functional spindle checkpoint, but a similar study found that further knockdown of 
Bub1 did abolish the spindle checkpoint, establishing the idea that only a very small amount 
of Bub1 is necessary for spindle checkpoint activity (4;5).  Sorger et al. (2005) found that as 
little as 2-5% of Bub1 was able to support checkpoint activity after spindle ablation, although 
they did not address loss of attachment (5).  Further work suggested that Bub1 was not 
required for arresting mitosis after complete ablation of the microtubules, but was necessary 
for responding to loss of tension (3).  Thus our findings of a tension dependent role for Bub1 
in the spindle checkpoint reflect much of the previous literature, but disagree with the recent 
finding that MEFs with 20 and 30% of endogenous Bub1 levels arrested for significantly less 
time than wildtype cells after nocodazole treatment.  There are several possible reasons for 
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this discrepancy. First, it is important to bear in mind that the Bub1∆2-3 allele is not merely 
expressed at low levels, but is also missing part of the N-terminus.  While we have not been 
able to sequence the Bub1∆2-3 protein, the most likely scenarios for expression of the 
Bub1∆2-3 allele are translation either from an ATG in exon 1, 5’ to the consensus start for 
Bub1, or translation from an internal ATG downstream of the deletion.  Analysis of the likely 
protein products determines that utilizing the upstream ATG would result in a predicted 
protein of 113 kDa versus 119 for the endogenous protein while internal ATG’s in the fourth 
and sixth exons are predicted to produce proteins of 106 and 99 kDa, respectively.  Based 
upon the size of the band detected by IP-western, translation from the upstream ATG is most 
likely, resulting in a protein missing exons 2 and 3 with approximately 10 residues of 
missense protein before exon 4.  The extreme N-terminus of Bub1 has not been well 
characterized but is highly conserved in nearly all organisms.  In fission yeast, checkpoint 
activity and kinetochore localization were mapped to residues 28 to 160 (6).  In contrast, 
Bub1 residues 200-300 were found to be required for SAC function and kinetochore 
localization in mammalian cells (7).  The Bub1∆2-3 allele most likely starts at residue 78, 
and contains the kinetochore localization domain, the Bub3 binding domain, and the kinase 
domain.  Chen (2004) demonstrated that a kinase dead Bub1 mutant or Bub1 with mutated 
MAPK phosphorylation sites (which also has deficient kinase activity) was able to restore 
checkpoint activity in response to large doses of Nocodazole, but not small doses, which 
affect tension, a similar phenotype to what we have observed (8).  However, as the kinase 
domain is in the last third of the Bub1 protein and the known MAPK phosphorylation sites 
are in the center third of the protein, it seems unlikely that either would be deleted.  It may be 
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helpful to perform in vitro studies on this protein to determine whether the Bub1∆2-3 protein 
retains kinase activity. 
 
Bub1 and tumorigenesis.  The first evidence for involvement of the spindle checkpoint in 
tumorigenesis was the discovery of Bub1 mutations in colorectal cancer cell lines (9).  Since 
this finding, mouse models of several SAC genes have demonstrated increased tumorigenesis 
with SAC disruption.  We have expanded on this finding by demonstrating that a survivable 
loss of Bub1 function leads to increased tumorigenesis.  With advanced aging, 78% of 
Bub1∆2-3/∆2-3 animals developed tumors versus 33% of wildtype animals.  While the majority 
of tumors in all three genotypes were liver tumors, there was also an increase in the tumor 
spectrum, with 13% of the Bub1∆2-3/∆2-3 mice developing lung tumors and one brain tumor 
was observed in the heterozygous cohort.  Analysis of hypomporphic alleles in the van 
Deursen lab revealed that mice expressing 30% and 20% of endogenous Bub1 levels had 
tumor incidences of 48% and 56%, respectively (1).  Together these data demonstrate that 
increasing loss of Bub1 leads to progressively higher levels of tumor development, 
coinciding with higher levels of aneuploidy in MEFs.  These results do not definitively 
answer the question whether aneuploidy contributes to tumorigenesis, but does provide 
further evidence for the role of the spindle checkpoint in preventing tumorigenesis.  An 
examination of other mouse models of SAC gene reveals increased incidence of 
tumorigenesis with increased aneuploidy, although different methodologies make direct 
comparisons difficult (Table 1).  Bub3 and Rae1 heterozygous animals (2 times wildtype 
levels of aneuploidy in MEFs) do not show significant increases in tumor development after 
DMBA treatment, but Bub3+/-;Rae1+/- animals (4 times wildtype levels of aneuploidy in 
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MEFs) develop significantly more tumors than control animals (10).  Mice heterozygous for 
Mad1 or Mad2 have a similar incidence of lung tumors as Bub1∆2-3/∆2-3 animals, but mice in 
these studies were necropsied at an earlier time point (18-19 months) than the Bub1 cohorts, 
making it difficult to compare overall tumor incidence rates (11;12).  One interesting 
exception is the lack of tumorigenesis observed in BubR1 hypomorphic mice despite high 
levels of aneuploidy (13).  These mice instead suffer from a progeroid phenotype with 
increased senescence and die prematurely, likely before tumors have a chance to develop. It 
is not known why BubR1 mice with high levels of aneuploidy suffer from this phenotype and 
Bub1 mutant mice with similar levels of aneuploidy do not, we can theorize that the BubR1 
interaction with p53 and its involvement in the DNA damage checkpoint may prime BubR1 
deficient cells to sensesce with the additional stress of aneuploidy development (14).   
 The tumor suppressor function of Bub1 likely works through two separate 
mechanisms: preventing aneuploidy by ensuring proper chromosome segregation, as well as 
responding to chromosome instability with induction of apoptosis or senescence.  Bub1 
prevents chromosome segregation errors by acting in the spindle assembly checkpoint, 
ensuring proper chromosome congression, and aiding localization of shugoshin (4;5;15). 
However, Bub1 may also be important for the cellular response to chromosome 
missegregation and aneuploidy.  Perera et al. (2007) found that while MEFs with endogenous 
Bub1 levels underwent apoptosis after missegregating chromosomes, Bub1 hypomorphic 
cells survived missegregation events at much higher frequencies (2).  In addition, Bub1 has 
been linked to the induction of senescence through a genetic screen for genes that by-pass 
senescence as well as the finding that Bub1 overexpression will also induce senescence 
(16;17).  Thus one can hypothesize a two-tiered prevention of tumorigenesis through 
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inhibition of chromosome instability.  Bub1 function is vital to the prevention of tumors first 
by preventing chromosome segregation errors, but if chromosomes are missegregated, Bub1 
prevents the propagation of aneuploid cells by induction of apoptosis or senescence pathways.   
The preponderance of evidence suggests that aneuploidy is a contributing factor to 
tumorigenesis, but aneuploidy may also function as a negative factor in tumorigenesis.  Work 
by Weaver et al. (2006) demonstrated that high levels of aneuploidy due to CENP-E 
heterozygozity can increase tumor development under some circumstances, but slows 
tumorigenesis in others (18).  They observed an increased incidence of spontaneous lung and 
spleen tumors, but a decrease in spontaneous liver tumor development and DMBA induced 
tumorigenesis. Furthermore, p19/ARF null mice had longer tumor free survival when 
heterozygous for CENP-E than p19ARF-/-;CENP-E+/+ controls.  High levels of aneuploidy 
potentially make it difficult for tumor cells to maintain mutations required for tumor growth 
and would quickly cause a loss of cellular viability.  Modeling chromosomal loss reveals a 
cell losing a single chromosome every cell cycle would suffer loss of both copies of a 
chromosome (a lethal event) within 8 divisions.  Loss of two or five chromosomes at each 
cell division would result in nullisomy within 5 and 4 generations respectively (Paul 
Schliekelman, personal communication).  This would represent a high level of chromosome 
loss and does not factor I gain of chromosomes, but does demonstrate the severe potential 
effects of aneuploidy.   
One interesting area of research that has not been investigated is whether tumors from 
mice with high levels of aneuploidy are karyotypically stable.  The ability to stabilize 
chromosome numbers would be greatly advantageous to tumor growth and is suggested by 
tumor types that have consistent aneuploidies but are karyptypically stable. It has also been 
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observed that early passage p53-null MEFs express low levels of BubR1 with resulting 
aneuploidy and karyotypic instability, but then increase BubR1 in later passages and are able 
to stabilize their karyotypes (19).  The ability to stabilize karyotypes during tumorigenesis 
obviously aids tumorigenesis in some circumstances.  This may explain why many tumors 
are aneuploid but do not have mutations in known SAC genes.  A mutation is an irreversible 
event whereas a change in gene expression is potentially more easily modified, thus 
karyptoypes could be potentially be stabilized by increasing expression of SAC genes, as in 
the example above of BubR1.  Further analysis of tumors from animals with defects in SAC 
genes could provide insight on this possibility. 
Telomere loss and the resulting chromosome instability provide evidence for loss and 
restoration of chromosome stability during tumorigenesis.  Maintenance of telomeres has 
been found to be a critical factor in preservation of genomic integrity with loss of telomere 
end-capping causing chromosomal inversions, deletions and translocations due to attempted 
repair of chromosome ends, or through gain and loss of whole chromosomes resulting from 
polyploidy events induced by telomere damage (20).  Telomere dysfunction has been shown 
to be inhibitory to tumor progression in APCMin mice, INK4A mutant mice, and DMBA-
treated mice due to activation of checkpoint pathways (21-23).  The chromosome instability 
observed with telomere dysfunction results in high levels of cell death that eliminate most 
cells, but some cells are able to survive this crisis point and immortalize.  The loss and later 
restoration of telomere maintenance provides a means of increasing chromosome instability 
temporarily.  In the correct genetic context, such as impaired p53, telomere dysfunction and 
chromosome instability can switch from being tumor suppressive to aiding malignant 
progression.   Perera et al. (2008) demonstrated that telomere dysfunction delayed tumor 
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formation and increased survivial in the K-Ras(G12D) mouse lung cancer model, but 
inactivating one allele of p53 decreased survival with development of highly metastatic and 
chromosomally unstable tumors (24).  Likewise, knockout of telomerase inhibited 
progression of hepatic neoplasias and p53 inactivation enabled advanced tumor formation 
(25). 
 
Bub1 and p53.  p53 is one of the most frequently mutated genes in human cancers and is a 
critical regulator of the cell cycle responsible for responding to many cellular stresses.  p53 
loss has been demonstrated to partially rescue the effects of Mad2 deletion in blastocysts and  
Bub1 knockdown in primary human fibroblasts.  Embryonic lethality observed in XRCC4 
(26), DNA ligase (27), and ∆11 BRCA1 (28) null mice is rescued with p53 inhibition or 
deletion.  We intercrossed Bub1∆2-3/+;p53+/- mice to determine if the perinatal lethality 
observed in Bub1∆2-3/∆2-3 mice may be due to p53 mediated effects, particularly induction of 
senescence.  However, we did not observe survival in Bub1∆2-3/∆2-3 animals with p53 loss and 
Bub1 heterozygozity even appeared to exacerbate lethality in p53 null females.  Survival of 
Bub1∆2-3/∆2-3;p53+/+ and Bub1∆2-3/∆2-3;p53-/- embryos to e13.5 and preliminary analysis 
indicating survival to e18.5, suggest that Bub1∆2-3/∆2-3;p53-/- animals die perinatally.  This 
surprising finding is supported by cell culture data, as Bub1∆2-3/∆2-3;p53-/- MEFs had 
significantly reduced growth compared to p53-/- MEFs, despite reducing senescence in 
Bub1∆2-3/∆2-3;p53-/- MEFs to low levels.  
 
What is happening to Bub1∆2-3/∆2-3 cells?  Our data provides evidence that Bub1 mutant 
cells suffer from a growth defect that does not appear to be cell death or senescence, due to 
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the lack of a significant difference in trypan blue staining or senescence associated ß-
galactosidase (SA-ß-gal) activity in Bub1∆2-3/∆2-3;p53-/- cells.  Preliminary data from live cell 
imaging of Bub1∆2-3/∆2-3 cultures reveals cycling time is not significantly different between 
wildtype and mutant cells and furthermore suggests that a much larger percentage of cells are 
not cycling than indicated by the senescence results, indicating growth arrest from a yet 
unknown cause (data not shown).  As stated above, we initially attributed the growth defect 
in Bub1∆2-3/∆2-3 cells to increased senescence, an irreversible growth arrest that is 
characterized by large cell size, increased metabolism, and increased SA-β-gal activity (29).   
The persistence of this growth defect in the absence of p53 and the lack of SA-β-gal activity, 
the most frequently used diagnostic for senescence, suggests the growth defect in Bub1∆2-3/∆2-
3 cells is not senescence.  However, senescence by the simplest definition of an irreversible 
growth arrest could likely be achieved by many different mechanisms.  Senescence, 
particularly in murine, cells is mediated primarily through the p53 pathway but can occur 
through p53-independent means as well (30-32).  Likewise, use of SA-β-gal activity as the 
exclusive marker for senescence may be misleading, as it marks increase in lysosmal content, 
a measure that’s relationship to senescence is unknown (33).  Senescent cells can generally 
be distinguished from quiescent or differentiated cells by increased metabolism, cell size, and 
cyclin D expression, thus analysis of these factors may provide evidence of senescence 
without SA-β-gal activity.  Bub1∆2-3/∆2-3 cells potentially could also be undergoing reversible 
growth through quiescence, although this is unlikely considering the high levels of growth 
factors in the cell culture conditions utilized, but further study is warranted.  Work in yeast 
has demonstrated a temporary G1 arrest in cells with chromosomal gains, as well as increases 
in glucose expression.  This phenomenon has not been observed in higher organisms, but the 
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yeast results indicate another potential cellular stress due to the extra energy requirements of 
the added gene expression and could be related to the Bub1∆2-3/∆2-3 phenotype. 
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Table 1  Aneuploidy and tumorigenesis in mouse models of SAC genes 
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Appendix A 
 
Fertility defects in Bub1 mutant mice 
Mice with severely reduced BubR1 levels were previously reported to be sterile. To 
determine if the Bub1∆2-3 mutation causes fertility defects, viable Bub1∆2-3/∆2-3 mice on the 
129/B6 mixed background were crossed to wildtype animals and litters were monitored.  
Bub1∆2-3/∆2-3 females were capable of carrying litters to term, although with small litter sizes. 
Three Bub1∆2-3/∆2-3 dams produced litters with an average litter size of 2.2 ± 1.1 (N=6 litters).  
However, Bub1∆2-3/∆2-3 males were sterile, with no litters born to 4 males crossed with 
wildtype females. Because the genetic background is highly variable and cannot be 
adequately controlled in animals derived from 129/B6 intercrosses, we also tested male 
fertility in (FVB)Bub1∆2-3/∆2-3 males. No litters were derived from 5 (FVB) Bub1∆2-3/∆2-3 
males when housed with wildtype FVB females, despite observation of copulation plugs. In 
contrast, 3 (FVB) Bub1+/+ littermate controls gave multiple litters each with average litter 
size of 6.5 ± 2.9 (N=11 litters). Surprisingly, testis weights, histology, sperm counts and 
motility were indistinguishable between (FVB)Bub1∆2-3/∆2-3 and (FVB)Bub1+/+ animals 
(Table 3). While sperm from ♀FVB x ♂(FVB)Bub1∆2-3/∆2-3 crosses fertilized normally, severe 
defects were observed upon in vitro culture.  66% (38/58) of embryos from ♀FVB x 
♂(FVB)Bub1+/+ intercrosses progressed to blastocyst stage, while only 8% (7/89) of embryos 
from ♀FVB x ♂(FVB)Bub1∆2-3/∆2-3 crosses developed into blastocysts. These results indicate 
that male sterility in Bub1∆2-3/∆2-3 mice is due to post-fertilization defects that impair embryo 
survival. We hypothesize that the defects may stem from severe aneuploidy in sperm from 
Bub1∆2-3/∆2-3 mice, although additional studies will be required to determine if this is the case. 
 
Bub1GT8 characterization 
In addition to the viability data presented in chapter 2, we have performed a cellular 
characterization on Bub1GT8/+ MEFs.  We examined spindle checkpoint function after 
treatment with nocodazole and found no significant difference in mitotic index between 
Bub1+/+ and Bub1GT8/+ MEF cultures, suggesting there is no haploinsufficiency with loss of 
one allele of Bub1 or the GT8 allele has partial function (Figure 1A). Bub1GT8/+ MEFs 
display similar rates of anaphase lagging chromosomes as Bub1+/+ MEFs, with 11% having 
lagging chromosomes (Figure 1B, with reference data from Chapter 2).  Bub1GT8/+ MEF 
cultures have similar rates of aneuploidy to Bub1∆2-3/+ cultures, with 31% and 23% 
respectively (Figure 1C, Bub1∆2-3/+ data from Chapter 2, Figure 3). 
 
Live cell imaging 
To determine the cause of growth defects in Bub1d/d MEF cultures, we performed live cell 
imaging.  This method allowed us to test whether the defect in growth rates may be due to 
slower progression through the cell cycle, and enabled the tracking of individual cells over 
several days.  Cells were plated at approximately 25,000 cells in wells of a 12-well plate the 
day prior to imaging.  Cells were kept at 37 degrees and treated with carbon dioxide during 
imaging, with pictures being taken every 10 minutes for 60 hours with a 20X objective.  
After images were obtained, data was analyzed by tracking each individual cell in the field 
over the course of 60 hours.  Cells were categorized as either being mitotic (cell divided), 
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rounding (cell rounded w/o dividing), non-cycling (no cell-rounding), and cell death (cell 
died during study).  In addition, time from entry into mitosis until the next mitosis, as 
determined by cell rounding, was measured.  We found little difference in mitotic timing 
with Bub1+/+ cell progressing through mitosis with an average of 13.0 ± 1.5 hours versus 
Bub1d/d which remained in mitosis for 12.7 ± 2.0 hours.  However, we observed a difference 
in cell fate with the live cell imaging, as 70% of Bub1+/+ cells progressed through mitosis 
compared to only 29% of Bub1d/d cells (Figure 2).  The Bub1d/d MEF cultures had more 
non-cycling (47%) and dying cells (11%) than Bub1+/+ cultures with 15% and 2% 
respectively.  These data suggest the majority of the growth defect found in Bub1d/d MEF 
cultures is due to cell arrest, although cell death plays a small role as well. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 112
Table 1.  Bub1Δ2-3 fertility measures 
Genotype 
Seminal 
Vesicle 
(Weight in g) 
Left Testis 
(Weight in g)
Right Testis 
(Weight in g)
Sperm 
Count 
(per cauda) 
Sperm 
motility
Δ2-3/Δ2-3 0.14 0.078  0.078 3.36×106 Normal
Δ2-3/Δ2-3  0.20 0.060 0.070 1.68×106 Normal
Δ2-3/Δ2-3 0.22 0.069 0.065 1.4×106 Normal
Δ2-3/Δ2-3  0.18 0.074 0.074 0.84×106 Normal
+/+ 0.20 0.08 0.080 0.28×106 Normal
+/+ 0.29 0.08 0.080 1.82×106 Normal
+/+ 0.33 0.08 0.080 4.2×106 Normal
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Figure 1 
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Figure 2 
 
 
 115
